

Washington University
Report on Federal Financial Assistance
Programs in Accordance with Uniform Guidance
For the Year Ended June 30, 2021
Employer Identification Number: 43-0653611

Washington University
Report on Federal Financial Assistance Programs in
Accordance with Uniform Guidance
Index
June 30, 2021

	Page(s)
A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION	
Report of Independent Auditors	1-2
Consolidated Financial Statements for the Years Ended June 30, 2021 and 2020.....	3-33
Schedule of Expenditures of Federal Awards	34-55
Notes to Schedule of Expenditures of Federal Awards	56
B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	57-58
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and On Internal Control Over Compliance in Accordance with the Uniform Guidance	59-60
C. SCHEDULE OF FINDINGS AND QUESTIONED COSTS	
Part I – Summary of Auditors’ Results	61
Part II – Financial Statement Findings	62
Part III – Federal Award Findings and Questioned Costs	62
D. SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS	
Part III – Summary Schedule of Prior Audit Findings and Status.....	63

Financial Statements and Supplemental Information



Report of Independent Auditors

To the Board of Trustees of Washington University:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statements of financial position as of June 30, 2021 and 2020, and the related consolidated statements of activities and of cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the University's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the University and its subsidiaries as of June 30, 2021 and 2020, and the changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.



Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2021 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. The information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated October 4, 2021 on our consideration of University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2021. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering University's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

St. Louis, Missouri
October 4, 2021

Washington University
Consolidated Statements of Financial Position
June 30, 2021 and 2020

(thousands of dollars)

	2021	2020
Assets		
Cash and cash equivalents	\$ 263,944	\$ 316,246
Investments	16,461,152	10,616,526
Accounts and notes receivable, net	646,996	552,592
Pledges receivable, net	407,232	441,909
Right-of-use assets	88,698	
Other assets	327,370	273,473
Fixed assets, net	<u>3,017,355</u>	<u>2,902,823</u>
Total assets	<u>\$ 21,212,747</u>	<u>\$ 15,103,569</u>
Liabilities		
Accounts payable and accrued expenses	\$ 623,047	\$ 575,332
Deposits, advances and other	34,280	33,388
Lease liability	99,666	
Professional liability	95,793	91,493
Deferred revenue and contract liabilities	161,045	158,348
Liabilities under split-interest agreements	40,883	38,690
Government supported student loans	17,550	22,671
Notes and bonds payable	<u>2,390,378</u>	<u>2,415,342</u>
Total liabilities	<u>3,462,642</u>	<u>3,335,264</u>
Net Assets		
Without donor restrictions	8,371,599	5,885,728
With donor restrictions	<u>9,378,506</u>	<u>5,882,577</u>
Total net assets	<u>17,750,105</u>	<u>11,768,305</u>
Total liabilities and net assets	<u>\$ 21,212,747</u>	<u>\$ 15,103,569</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
Year Ended June 30, 2021

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 433,334	\$	\$ 433,334
Endowment spending distribution	354,542	11,237	365,779
Investment return	10,933	184	11,117
Gifts	76,625	81,829	158,454
Grants and contracts revenues			
Direct costs recovered	507,306		507,306
Facilities and administrative costs recovered	194,793		194,793
Patient services, net	1,667,815		1,667,815
Auxiliary enterprises - sales and services	90,249		90,249
Educational activities - sales and services	215,868		215,868
Affiliated hospital revenues	154,448		154,448
Other revenue	38,492	2	38,494
Net assets released from restrictions	107,829	(107,829)	-
Total Revenues and other support	3,852,234	(14,577)	3,837,657
Expenses:			
Compensation expense	2,252,936		2,252,936
Supplies, services, and other	1,124,898		1,124,898
Depreciation expense	213,825		213,825
Interest expense	71,485		71,485
Total expenses	3,663,144	-	3,663,144
Net operating results	189,090	(14,577)	174,513
Non-operating revenues and (expenses):			
Investment returns net of endowment spending	2,323,518	3,417,121	5,740,639
Permanently restricted gifts		71,323	71,323
Other non-operating	(26,737)	22,062	(4,675)
Non-operating, net	2,296,781	3,510,506	5,807,287
Change in net assets	2,485,871	3,495,929	5,981,800
Net Assets, Beginning of the Year	5,885,728	5,882,577	11,768,305
Net Assets, End of the Year	\$ 8,371,599	\$ 9,378,506	\$ 17,750,105

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
Year Ended June 30, 2020

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 451,500	\$	\$ 451,500
Endowment spending distribution	351,383	10,489	361,872
Investment return	19,990	1,182	21,172
Gifts	101,843	142,845	244,688
Grants and contracts revenues			
Direct costs recovered	483,265		483,265
Facilities and administrative costs recovered	177,421		177,421
Patient services, net	1,482,562		1,482,562
Auxiliary enterprises - sales and services	102,434		102,434
Educational activities - sales and services	183,974		183,974
Affiliated hospital revenues	146,460		146,460
Other revenue	94,352	2	94,354
Net assets released from restrictions	123,173	(123,173)	-
Total Revenues and other support	3,718,357	31,345	3,749,702
Expenses:			
Compensation expense	2,183,944		2,183,944
Supplies, services, and other	1,103,911		1,103,911
Depreciation expense	201,973		201,973
Interest expense	70,200		70,200
Total expenses	3,560,028	-	3,560,028
Net operating results	158,329	31,345	189,674
Non-operating revenues and (expenses):			
Investment returns net of endowment spending	307,030	171,445	478,475
Permanently restricted gifts		80,184	80,184
Other non-operating	(56,517)	27,557	(28,960)
Non-operating, net	250,513	279,186	529,699
Change in net assets	408,842	310,531	719,373
Net Assets, Beginning of the Year	5,476,886	5,572,046	11,048,932
Net Assets, End of the Year	\$ 5,885,728	\$ 5,882,577	\$ 11,768,305

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Cash Flows
Years Ended June 30, 2021 and 2020

(thousands of dollars)

	2021	2020
Cash flows from operating activities		
Change in net assets	\$ 5,981,800	\$ 719,373
Adjustments to reconcile change in net assets to cash provided by operating activities		
Realized and unrealized net gains on investments	(6,177,960)	(899,464)
Depreciation expense	213,825	201,973
Permanently restricted gifts	(71,323)	(80,184)
Investments received as gifts - not permanently restricted	(12,173)	(11,070)
Proceeds from sales of investments received as gifts	12,173	11,070
Debt extinguishment costs		9,635
Operating leases	10,968	
Other non-cash adjustments	29,908	59,127
Changes in assets and liabilities		
Accounts and notes receivable, net	(67,005)	47,113
Pledges receivable, net	30,454	(49,691)
Accounts payable and accrued expenses	46,248	(6,907)
Other assets and liabilities	(52,379)	18,984
Net cash (used)/provided by operating activities	<u>(55,464)</u>	<u>19,959</u>
Cash flows from investing activities		
Proceeds from sales and maturities of investments	6,909,906	5,805,217
Purchases of investments	(6,612,196)	(5,925,802)
Purchases of fixed assets	(345,458)	(397,220)
Student loans disbursed	(14,376)	(15,516)
Student loan payments received	20,565	20,459
Other		45
Net cash used in investing activities	<u>(41,559)</u>	<u>(512,817)</u>
Cash flows from financing activities		
Principal payments of debt	(185,011)	(150,436)
Proceeds from long-term debt issuance	159,486	509,037
Contributions restricted for long-term investment	65,002	55,465
Proceeds from sales of investments received as gifts	10,400	19,152
Debt extinguishment costs		(9,635)
Other	(5,156)	(14,579)
Net cash provided by financing activities	<u>44,721</u>	<u>409,004</u>
Net decrease in cash	<u>(52,302)</u>	<u>(83,854)</u>
Cash and cash equivalents		
Beginning of year	<u>316,246</u>	<u>400,100</u>
End of year	<u>\$ 263,944</u>	<u>\$ 316,246</u>
Supplemental data		
Interest paid in cash	\$ 71,662	\$ 66,566
Noncash activities		
Contributions of securities and other noncash assets	23,103	36,211
Net change in accounts payable for investments	1,470	(114,118)
Right-of-use assets obtained in exchange for lease liabilities	686	

The accompanying notes are an integral part of these consolidated financial statements.

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

1. Summary of Significant Accounting Policies

Organization

Washington University in St. Louis (the “university”), is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

Basis of Presentation and Use of Estimates

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates. Significant consolidated affiliates include The Barnard Free Skin and Cancer Hospital, Parallel Properties LLC including its affiliates, Washington University Clinical Associates, LLC and associated physician practices, and Washington University Physicians in Illinois, Inc.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for doubtful accounts. Actual results could differ from those estimates.

Net Assets

Resources are recorded based on the absence or existence of donor-imposed restrictions. Descriptions of the net asset categories follow:

- Net assets without donor restrictions are free of donor-imposed restrictions. Board-designated endowment funds are also included within net assets without donor restrictions.
- Net assets with donor restrictions represent net assets that consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time as well as gifts and trusts which, by donor restriction, are required to be held in perpetuity. Net assets required to be held in perpetuity at June 30, 2021 and 2020, are \$2,442,688 and \$2,365,401, respectively.

Revenues from sources other than contributions and investment returns are reported as increases in net assets without donor restrictions. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose donor restrictions that are met in the same fiscal year they are received are included in revenues without donor restrictions. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

endowments. Such amounts remain in net assets with donor restrictions until appropriated for expenditure. When a donor restriction expires due to the passage of time or the university's fulfillment of donor stipulated purpose, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions. Donor restricted gifts that are to be held in perpetuity are reported in the non-operating section of the consolidated statements of activities. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in net assets without donor restrictions.

The university's net assets as of June 30, 2021 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$	\$ 8,268,427	\$ 8,268,427
Board-designated endowment funds	4,753,833	645,821	5,399,654
Investment in plant, net	790,380		790,380
Pledges		407,232	407,232
Other donor-restricted		57,026	57,026
Operating and other reserves	<u>2,827,386</u>		<u>2,827,386</u>
	<u>\$ 8,371,599</u>	<u>\$ 9,378,506</u>	<u>\$ 17,750,105</u>

The university's net assets as of June 30, 2020 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$	\$ 5,103,500	\$ 5,103,500
Board-designated endowment funds	3,085,820	299,974	3,385,794
Investment in plant, net	762,165		762,165
Pledges		441,909	441,909
Other donor-restricted		37,194	37,194
Operating and other reserves	<u>2,037,743</u>		<u>2,037,743</u>
	<u>\$ 5,885,728</u>	<u>\$ 5,882,577</u>	<u>\$ 11,768,305</u>

Investments

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the consolidated statements of activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

At June 30, 2021 and 2020, investments include \$163,403 and \$274,683, respectively, purchased with unexpended proceeds from the Series 2017 A Missouri Health and Educational

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

Facilities Authority (MOHEFA) revenue bonds issued July 6, 2017 and the Series 2020A taxable revenue bonds issued April 3, 2020. The 2017A MOHEFA funds and the 2020A bond funds may be utilized for the purposes set forth in the relevant bond documents.

Fixed Assets

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation, computed on a straight-line basis over the estimated useful lives of the assets. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Fixed assets by classification at June 30, 2021 and 2020 consist of the following:

	<u>2021</u>	<u>2020</u>
Construction in progress	\$ 320,701	\$ 311,806
Land and improvements to land	190,825	178,356
Buildings	4,743,990	4,502,505
Equipment	<u>663,409</u>	<u>619,921</u>
Total cost	5,918,925	5,612,588
Accumulated depreciation	<u>(2,901,570)</u>	<u>(2,709,765)</u>
Total fixed assets, net	<u>\$ 3,017,355</u>	<u>\$ 2,902,823</u>

Collections

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. They are neither disposed of for financial gain nor encumbered in any manner. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

Leases

The university determines if an arrangement is or contains a lease at inception based on whether the contract conveys the right to control the use of identified property, plant, or equipment in exchange for consideration. The university has both leases under which it is obligated as a lessee and leases for which it is the lessor. Operating leases in which the university is a lessee are included in right-of-use (ROU) assets and lease liabilities on the consolidated statements of financial position. The university has elected the short-term lease exception under ASC 842 for all leases, and therefore, leases with an initial term of 12 months or less are not included on the consolidated statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The interest rate implicit in lease contracts is typically not readily determinable, and as such, the university uses its collateralized borrowing rate using a period comparable with the lease term in determining the present value of lease payments. The lease term may, at the university's discretion, include options to extend or to terminate the lease that the university is

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

reasonably certain to exercise. Lease expense for lease payments is recognized on a straight-line basis over the lease term within the supplies, services and other line of the consolidated statement of activities. Variable lease payments based on an index or rate, such as the consumer price index, are initially measured using the index or rate in effect at lease commencement. The university has lease agreements with non-lease components that relate to the lease components. The university elected the practical expedient to account for non-lease components and the lease components to which they relate as a single lease component for all leases. Leasing arrangements for which the university is the lessor are not material to the consolidated financial statements.

Financing Receivables

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins and Health Professional Student Loan programs. Loan funds are reported at estimated realizable value, as it is not practical to determine the fair value of loan fund receivables, which include a large component of federally sponsored student loans. Federally sponsored student loans have significant government restrictions as to marketability, interest rates, and repayment terms. Federal funds are ultimately refundable to the government and are recognized as a liability in the consolidated statements of financial position.

The university's loan portfolio includes over 5,800 individual loans and is geographically diverse. Loans are considered past due if the minimum payment is not received within thirty-one days past the due date. At June 30, 2021 and 2020, respectively 95% and 94% of the parent loans and 73% and 74% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

Deferred Revenue and Contract Liabilities

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are clinical trial receipts, grants and contracts, and prepaid tuition and housing.

Tuition and Fees

Tuition and fee revenue, net of scholarships and other implicit price concessions, is recognized over-time using the output method of measuring progress in the fiscal year in which the educational programs are conducted. Students are invoiced at the commencement of each academic period. Payment is due when invoiced. The performance obligation, delivery of educational services, is satisfied as services are rendered. If delivery of the performance obligation is not complete as of fiscal year-end, a contractual liability is recorded. The deferred contract liability at June 30, 2021 and 2020 was \$50,657 and \$45,962, respectively, and is reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to students by the university, including aid provided to employees and their dependents, for the years ended June 30, 2021 and 2020, respectively, was \$423,790 and \$413,029.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The table below identifies student aid by type. Scholarships are reported net against tuition in the consolidated statements of activities. Other amounts are reported as expenses.

	2021	2020
Scholarships from unrestricted sources	\$ 227,169	\$ 221,068
Scholarship support from gifts, endowment and other restricted sources	<u>77,632</u>	<u>74,081</u>
Total scholarships	304,801	295,149
Employee and dependent tuition benefits	38,198	38,446
Stipends	79,221	77,326
Work study	<u>1,570</u>	<u>2,108</u>
Total	<u>\$ 423,790</u>	<u>\$ 413,029</u>

Gifts

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.20% to 2.04%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors.

A summary of pledges receivable is as follows:

	2021	2020
In one year or less	\$ 152,990	\$ 165,399
Between two and five years	145,371	153,459
Over five years	<u>125,702</u>	<u>144,145</u>
	424,063	463,003
Less:		
Discount	(8,132)	(12,540)
Allowance for uncollectible amounts	<u>(8,699)</u>	<u>(8,554)</u>
Total	<u>\$ 407,232</u>	<u>\$ 441,909</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

Grants and Contracts

The university receives grant and contract revenue from governmental and private sources. Revenue associated with the direct costs of sponsored programs is generally recognized as the related costs are incurred. At contract inception, the university determines whether the goods or services to be provided are to be accounted for as a single performance obligation or as multiple performance obligations. If multiple performance obligations are identified, the university generally uses the cost plus a margin approach to determine the relative standalone selling price of each performance obligation. Revenue from these contracts is earned over-time. Invoicing of the customer, if required, will generally be in accordance with terms of the contract with payment due when invoiced. Generally, the time between the receipt of payment and the transfer of goods and service under these contracts is less than one year.

The university records revenue without donor restrictions upon its recovery of direct and indirect costs applicable to those sponsored programs that provide for the full or partial reimbursement of such costs. Most grants awarded to the university by government agencies are conditional contributions. The principle condition attached to these awards is that the university must incur costs in accordance with the Office of Management and Budget's uniform guidance before costs can be reimbursed. Total amounts promised under these grants for which conditions have not yet been fulfilled are approximately \$889,722 and \$879,544 at June 30, 2021 and June 30, 2020, respectively. The recovery of indirect costs, also referred to as facilities and administrative costs is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of federally sponsored programs is at rates negotiated with the Department of Health and Human Services.

In some cases, the sponsor will prepay amounts in anticipation of costs to be incurred. In those cases, amounts received in excess of costs incurred are recorded as contract liabilities.

Patient Services Revenue

Net patient service revenue is reported at the amount that reflects the consideration to which the university expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including health insurers and government programs), and others. Generally, the university bills the patient and third-party payers several days after the services are performed. Revenue is recognized as performance obligations are satisfied.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges which provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, the university has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

Generally patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The university also provides services to

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. The university determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The university determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as there are a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. The effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Contractual adjustments to patient service revenue were \$2.13 billion and \$1.84 billion for the years ended June 30, 2021 and 2020, respectively.

The university has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. In certain instances, the university may enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The university reported net accounts receivable for patient services of \$175,945 and \$144,755, at June 30, 2021 and 2020, respectively.

Auxiliary Enterprises – Sales and Services

Auxiliary enterprises sales and services revenue is primarily earned over-time utilizing the output method of measuring progress. Auxiliary enterprise sales and services contracts will generally constitute a single performance obligation as there is a single promise. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees with separate contracts for each type of service. Housing, dining services and parking fees are invoiced to undergraduate students at the beginning of each academic period. Payment is due upon invoice issuance. Graduate students and undergraduates who live off campus sign rental agreements providing for monthly rent payments. Each contract for services in this category has a duration of one year or less. A contract liability is recorded for the delivery of performance obligations that is not completed prior to the fiscal year end.

Educational Activities – Sales and Services

Clinical trial revenue is earned over-time as the university provides services. The transaction price is negotiated with the customer and is usually based on standard rates for clinical services and the expected cost to complete the contract. Payment terms under these contracts vary but generally provide for the right to invoice the customer as work progresses, either based on units performed or the achievement of billing milestones. The university has determined that an input method using costs incurred as a basis to estimate revenue earned best depicts the pattern of transfer of control to the customer. In those limited cases where prepayments are significant, revenue is deferred until earned and a contract liability is recorded. The contract liabilities at June 30, 2021 and 2020 are \$50,800 and \$56,325,

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

respectively, and are reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Contracts in other educational sales and services cover a broad range of activities including physician services to affiliated and unaffiliated hospitals, executive education program fees and royalties. Revenue from the contracts in this category is earned over time as services are rendered. The measure of progress varies according to the nature of the services provided. Invoicing to customers is performed in the cadence required under the contracts and amounts invoiced generally are considered due upon receipt. Accruals for services provided but not yet invoiced are recorded at year end. Amounts receivable under service contracts are \$64,239 and \$72,635 at June 30, 2021 and 2020, respectively. Fees for executive education programs are often received in advance of the program and represent a contract liability. Such amounts are reported as deferred revenue and contract liabilities in the consolidated statement of financial position.

Affiliated Hospital Revenues

Affiliated hospital revenue is earned over-time as the various services are provided as an integrated performance obligation as more fully described in footnote 13. The measure of progress towards completion of those obligations is based on the day-to-day operations of the university's School of Medicine and the affiliated hospitals. Payments are received under the agreement semiannually. Amounts receivable under the agreement are \$74,708 and \$68,577 at June 30, 2021 and 2020 respectively.

Operating Results

The university's measure of operations as presented in the consolidated statements of activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the consolidated statements of activities as incurred for employee compensation, depreciation, interest and supplies, services and other. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, contributions to be held in perpetuity, and other non-operating amounts.

Split-Interest Agreements

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is a credit-adjusted rate in existence at the date of the gift. The rates used range from 0.53% to 1.98% for 2021 and 1.37% to 2.31% for fiscal year 2020. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries. For the years ending June 30, 2021 and 2020, the change in fair value was an increase of \$1,661 and a decrease of \$2,964, respectively. As of June 30, 2021

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

and 2020, the university's liability under charitable gift annuities was \$18,248 and \$19,710, respectively.

Cash and Cash Equivalents

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as investments, to be cash and cash equivalents.

Income Taxes

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income, or consolidated for-profit affiliates incur taxes. The Tax Cuts and Jobs Act (the "Act") was enacted on December 22, 2017. The Act impacts the university in several ways, including new excise taxes on executive compensation and net investment income, increases to unrelated business taxable income (UBTI), changes to the net operating loss rules, repeal of the alternative minimum tax (AMT), and the computation of UBTI separately for each unrelated trade or business. Further, the Act reduces the U.S. federal corporate tax rate and federal corporate unrelated business income tax rate from 35% to 21%.

As of June 30, 2021, the university has made a reasonable estimate of the determinable effects of the enactment of the Act on existing deferred tax balances. These amounts are provisional, subject to change and not material to the university's consolidated financial statements. Management believes the university has no uncertain tax positions that result in material unrecognized tax expense/benefits.

Effects of the Pandemic

The outbreak of COVID -19 has caused domestic and global disruption in operations for institutions of higher education. The impact (i) may affect the cost of operations and (ii) may materially affect financial markets and consequently the returns on and value of the university's investments. Other adverse consequences of COVID-19 or any other similar outbreaks in the future may include, but are not limited to, decline in enrollment, decline in demand for university housing and decline in demand for university programs that involve travel or have international connections. The full impact of COVID-19 or any other similar outbreaks in the future and the scope of any adverse impact on the university's finances and operations cannot be fully determined at this time.

The university received funding from the federal Coronavirus Aid, Relief and Economic Security ("CARES") Act Provider Relief Fund, recognized as a portion of "Other Revenues" in the consolidated statement of activities as of June 30, 2020, to be retained and used only for reimbursement of eligible expenses and lost revenues in accordance with laws, regulations and guidance issued by the U.S. Department of Health and Human Services.

Recent Accounting Pronouncements

During fiscal 2016, the FASB issued ASU 2016-02, Leases, along with subsequently issued supplemental ASUs (collectively, ASC 842). This guidance requires lessees to recognize a lease liability and a ROU asset on a discounted basis, for substantially all leases, as well as provide

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

additional disclosures regarding leasing arrangements (refer to footnote 8). The university adopted this standard as of July 1, 2020, the effective date, and applied the guidance to each lease that existed as of that date. As a result, prior comparative periods were not adjusted. The university elected the package of practical expedients under the new standard, which permits entities to not reassess lease classification, lease identification or initial direct costs for existing or expired leases prior to the effective date. The university capitalized ROU assets and lease liabilities of \$104,504 and \$117,989, respectively, on the balance sheet at July 1, 2020 with the excess of lease liabilities over ROU assets charged to net assets without donor restrictions. Upon adoption, there was no material change to the consolidated net assets, statements of activities, or cash flows.

ASU 2016-13, *Measurement of Credit Losses on Financial Instruments*, was issued by the FASB during June 2016 and was adopted by the university during fiscal year 2021. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. This is a shift from the previous probable loss model to an expected loss model which requires an estimate of the future collectability of cash flows. The amendments in this update broaden the information an entity must consider when developing its expected credit loss estimate such as past events, historical loss, experience with similar assets, and current market and economic conditions. There was no significant impact to the university's financial statements or footnote disclosures upon adoption.

In August 2018, the FASB issued ASU 2018-13, *Changes to the Disclosure Requirements for Fair Value Measurement*, which was adopted by the university as of July 1, 2020 (see footnote 2). The standard removes the requirements to disclose transfers between Level 1 and Level 2 of the fair value hierarchy and the changes in unrealized gains and losses for recurring Level 3 fair value measurements, among other disclosures. The standard modifies other disclosure requirements regarding transfers into and out of Level 3 of the fair value hierarchy and investments in entities that calculate net asset value. Finally, the standard adds requirements for disclosures for information surrounding the unobservable input used to develop Level 3 fair value measurements.

ASU 2020-07, *Presentation and Disclosure by Not-for-Profit Entities for Contributed Nonfinancial Assets*, was issued by the FASB in September 2020 in order to address stakeholders' concerns regarding lack of transparency in the measurement of contributed nonfinancial assets as well as the amount of those contributions used in the university's programs and other activities. Under this ASU, nonprofit entities should present contributed nonfinancial assets as a separate line item in the consolidated statement of activities and also quantitatively disclose the disaggregation of such assets by type. In addition, an entity should disclose various qualitative information regarding the assets such as valuation techniques, how the assets were used, restrictions on use, etc. While the ASU adds presentation and disclosure requirements, it does not change the recognition and measurement requirements for contributed nonfinancial assets. The ASU is effective for annual periods beginning after June 15, 2021, however, the university has chosen to early adopt this guidance during the current fiscal year. Contributed nonfinancial assets are not material to the university's financial statements and, therefore, line-item presentation and disclosure requirements have been omitted.

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

2. Fair Value

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university's assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2021, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$774,142.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2021
Investments					
Public equity					
Domestic	\$ 290,611			\$ 1,625,359	\$ 1,915,970
International	61,800			2,948,440	3,010,240
Fixed income - Nominal		1,076,289			1,076,289
Absolute return				1,027,832	1,027,832
Private capital			254,301	7,741,398	7,995,699
Short-term investments	348,033	11,756			359,789
Real assets			749	715,436	716,185
Other investments	210,017	749	68,022	36,946	315,734
Total investments at fair value	910,461	1,088,794	323,072	14,095,411	16,417,738
Investments not reported at fair value					
Affiliates - Equity basis					40,876
Accrued investment income					2,538
Total investments	\$ 910,461	\$ 1,088,794	\$ 323,072	\$ 14,095,411	\$ 16,461,152

The following table presents the financial instruments carried at fair value as of June 30, 2020, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$656,460.

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2020
Investments					
Public equity					
Domestic	\$ 134,100	\$ 27		\$ 938,834	\$ 1,072,961
International	96,173			2,098,450	2,194,623
Fixed income - Nominal		820,224			820,224
Absolute return				1,015,840	1,015,840
Private capital			158,996	4,224,579	4,383,575
Short-term investments	137,437	3,824			141,261
Real assets			2,128	534,686	536,814
Other investments	314,574	(650)	69,724	31,241	414,889
Total investments at fair value	682,284	823,425	230,848	8,843,630	10,580,187
Investments not reported at fair value					
Affiliates - Equity basis					33,561
Accrued investment income					2,778
Total investments	\$ 682,284	\$ 823,425	\$ 230,848	\$ 8,843,630	\$ 10,616,526

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all. Trustees determine the valuation for beneficial interest trusts and split-interest agreements. Strategic real estate is valued at historical cost and is evaluated annually for impairment.

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private capital investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2021:

Investments	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$	No Limit	Daily to annually, with same day-180 day notice	Lock-up provision periods range from 0 to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments		No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return		No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from 0 to 3 years. Certain investments include side pockets subject to external manager discretion.
Private capital	1,691,267	0 - 28 Years	Not eligible for redemption	Not redeemable
Real assets	337,723	0 - 11 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 2,028,990</u>			

Footnote (1): Includes \$21 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2020:

Investments	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 1,805	2 Years - No Limit	Daily to annually, with 1 day-1 year notice	Lock-up provision periods range from 0 to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments		No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return		1 Year - No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from 0 to 3 years. Certain investments include side pockets subject to external manager discretion.
Private capital	1,700,420	0 - 29 Years	Not eligible for redemption	Not redeemable
Real assets	335,813	0 - 11 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 2,038,038</u>			

Footnote (1): Includes \$28 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Public Equities

Public equities include investments in publicly-traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled comingled funds which are valued at NAV as described above. Investments held in custody accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to equity hedged and event driven. These funds are valued at net asset value as described above.

Private Capital

Investments in private capital strategies are made in targeted categories including growth equity, venture capital, distressed credit, and corporate finance. Redemptions of such funds are not permitted and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in non-redeemable fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

The following tables roll forward the consolidated statement of financial position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2021 and 2020.

	Balance	Net Realized	Purchases, Sales	Transfers	Balance
	June 30, 2020	and Unrealized	and Settlements	in/(out) of	June 30, 2021
		Gains (Losses)	Net	Level 3, net	
Investments (by strategy)					
Private capital	\$ 158,996	\$ 246,611	\$ (202,365)	\$ 51,059	\$ 254,301
Real assets	2,128	101	(1,480)		749
Other investments	69,724	9,928	2,519	(14,149)	68,022
Total	<u>\$ 230,848</u>	<u>\$ 256,640</u>	<u>\$ (201,326)</u>	<u>\$ 36,910</u>	<u>\$ 323,072</u>

	Balance	Net Realized	Purchases, Sales	Transfers	Balance
	June 30, 2019	and Unrealized	and Settlements	in/(out) of	June 30, 2020
		Gains (Losses)	Net	Level 3, net	
Investments (by strategy)					
Private capital	\$ 130,923	\$ (1,296)	\$ 31,425	\$ (2,056)	\$ 158,996
Real assets	110,600	363	(108,835)		2,128
Other investments	70,183	643	102	(1,204)	69,724
Total	<u>\$ 311,706</u>	<u>\$ (290)</u>	<u>\$ (77,308)</u>	<u>\$ (3,260)</u>	<u>\$ 230,848</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2021 and 2020 respectively, reported as investment returns net of endowment spending in the consolidated statements of activities by type of investment is:

	2021	2020
Private capital	\$ 43,818	\$ (129)
Real assets	(823)	3,973
Other investments	8,023	(341)
Total	<u>\$ 51,018</u>	<u>\$ 3,503</u>

3. Investment Return

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private capital categories, report investment returns net of fees.

	2021	2020
Investment income	<u>\$ 11,117</u>	<u>\$ 21,172</u>
Pooled endowment dividends and interest income, net of investment management fees	(71,542)	(59,117)
Pooled endowment distribution in excess of income	<u>437,321</u>	<u>420,989</u>
Pooled endowment spending distribution	<u>365,779</u>	<u>361,872</u>
Investment gains, net	6,177,960	899,464
Gains distributed as endowment distribution	<u>(437,321)</u>	<u>(420,989)</u>
Investment gains net of endowment spending distribution	<u>5,740,639</u>	<u>478,475</u>
Net investment return	<u>\$ 6,117,535</u>	<u>\$ 861,519</u>

4. Endowment

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2021, the university's endowment consists of 3,785 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as net assets with donor restrictions, (a) the original value of gifts donated to the donor-restricted endowment, (b) the original value of subsequent gifts to the donor-restricted endowment, (c) accumulations to the donor-restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of donor-restricted endowment funds that are not restricted in perpetuity are considered restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2021:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$	\$ 8,268,427	\$ 8,268,427
Board-designated endowment funds	<u>4,753,833</u>	<u>645,821</u>	<u>5,399,654</u>
Total endowment funds	<u>\$ 4,753,833</u>	<u>\$ 8,914,248</u>	<u>\$ 13,668,081</u>

Changes in endowment net assets for the year ended June 30, 2021:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	<u>\$ 3,085,820</u>	<u>\$ 5,403,474</u>	<u>\$ 8,489,294</u>
Investment return			
Net investment income	(29,528)	(40,961)	(70,489)
Net appreciation (realized and unrealized)	<u>2,468,932</u>	<u>3,714,753</u>	<u>6,183,685</u>
Total investment return	2,439,404	3,673,792	6,113,196
Gifts	109	78,578	78,687
Appropriation of endowment assets for expenditure	(150,971)	(214,808)	(365,779)
Net transfers of funds	29,884	2,797	32,681
Allocation of endowment return to treasurer's investment pool	(653,549)	(29,804)	(683,353)
Other activity	<u>3,136</u>	<u>219</u>	<u>3,355</u>
Endowment net assets, end of year	<u>\$ 4,753,833</u>	<u>\$ 8,914,248</u>	<u>\$ 13,668,081</u>

Of the amount classified as endowment net assets with donor restrictions, \$ 5,540,335 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

Endowment net asset composition by type of fund as of June 30, 2020:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$	\$ 5,103,500	\$ 5,103,500
Board-designated endowment funds	3,085,820	299,974	3,385,794
Total endowment funds	<u>\$ 3,085,820</u>	<u>\$ 5,403,474</u>	<u>\$ 8,489,294</u>

Changes in endowment net assets for the year ended June 30, 2020:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	<u>\$ 2,845,594</u>	<u>\$ 5,163,331</u>	<u>\$ 8,008,925</u>
Investment return			
Net investment income	(24,515)	(33,356)	(57,871)
Net appreciation (realized and unrealized)	446,000	438,638	884,638
Total investment return	<u>421,485</u>	<u>405,282</u>	<u>826,767</u>
Gifts	83	79,937	80,020
Appropriation of endowment assets for expenditure	(150,064)	(211,808)	(361,872)
Net transfers of funds	15,834	(2,815)	13,019
Allocation of endowment return to treasurer's investment pool	(51,171)	(28,772)	(79,943)
Other activity	<u>4,059</u>	<u>(1,681)</u>	<u>2,378</u>
Endowment net assets, end of year	<u>\$ 3,085,820</u>	<u>\$ 5,403,474</u>	<u>\$ 8,489,294</u>

Of the amount classified as endowment net assets with donor restrictions, \$2,686,050 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment by Purpose

The purpose of endowment funds as of June 30, 2021:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 3,479,522	\$ 6,052,357	\$ 9,531,879
Restricted for student assistance	687,806	1,571,424	2,259,230
Restricted for buildings and renovations	586,505	1,244,725	1,831,230
Life income		45,742	45,742
Total endowment net assets	<u>\$ 4,753,833</u>	<u>\$ 8,914,248</u>	<u>\$ 13,668,081</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The purpose of endowment funds as of June 30, 2020:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 2,321,054	\$ 3,621,441	\$ 5,942,495
Restricted for student assistance	407,464	1,013,383	1,420,847
Restricted for buildings and renovations	357,278	743,597	1,100,875
Life income	24	25,053	25,077
Total endowment net assets	<u>\$ 3,085,820</u>	<u>\$ 5,403,474</u>	<u>\$ 8,489,294</u>

Endowment Funds with Deficits

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they remain classified as net assets with donor restrictions. Deficits of this nature were immaterial as of June 30, 2021 and 2020. The deficits resulted largely from unfavorable market fluctuations.

Return Objectives and Risk Parameters

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2021, the spending rate from the pooled endowment was 4.4% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

The university's endowment assets at June 30 are as follows:

	2021	2020
Pooled endowment and other funds	\$ 15,310,698	\$ 9,547,820
Life income trusts and pools	88,583	76,091
Externally administered trusts	37,338	30,804
Separately invested endowment	9,674	8,577
Total	15,446,293	9,663,292
Less: Operating funds invested in pool	(1,780,908)	(1,148,092)
Net endowment assets	\$ 13,665,385	\$ 8,515,200

The amounts above include term endowments of \$150,012 and \$102,870 as of June 30, 2021 and 2020, respectively.

5. Liquidity and Availability of Resources

At June 30, 2021 and 2020, the university's financial assets available for general expenditures within one year of the balance sheet date are as follows:

	2021	2020
Total assets at year end	\$ 21,212,747	\$ 15,103,569
Less:		
Accounts and notes receivable due in more than one year	(96,258)	(104,244)
Pledges receivable unavailable for general expenditure	(307,854)	(332,861)
Donor-restricted endowment funds	(8,283,442)	(5,135,123)
Board-designated endowment funds	(5,381,943)	(3,380,077)
Other long-term investments	(2,089,396)	(1,590,748)
Right-of-use assets	(88,698)	
Other assets	(327,370)	(273,473)
Fixed assets	(3,017,355)	(2,902,823)
Total financial assets available within one year	\$ 1,620,431	\$ 1,384,220

The university's endowment funds consist of donor-restricted and board-designated endowment funds. As described in Note 4, the university has an endowment spending distribution policy with a spending rate range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For fiscal year 2022, the Board of Trustees approved a spending rate which will generate an endowment payout equaling or exceeding that of fiscal year 2021, including an allocation to the treasurer's investment pool, that will be available for operations during fiscal year 2022.

In addition to these available financial assets, the university's annual expenditures will be primarily funded by current year operating revenues including tuition, patient services income, and sponsored research income. As part of the university's liquidity management, a policy is in place to structure its financial assets to be available as general expenditures, liabilities, and other obligations come due. The university also invests cash in excess of daily

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

requirements in short-term investments. Furthermore, although the university does not intend to spend from its board-designated endowment funds other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment that are free from investment restrictions could be made available if necessary. Other long-term investments are primarily composed of amounts designated by the university as reserves. Such investments are without donor restriction and could be drawn upon in the event of extreme stress. In the event of an unanticipated liquidity need, the university could also draw upon \$250,000 of available lines of credit at June 30, 2021.

6. Accounts and Notes Receivable

Accounts and notes receivable at June 30 were as follows:

	2021	2020
Patient services	\$ 489,726	\$ 418,149
Student and parent loans		
Parent loan fund	43,037	44,928
Government student loans	15,656	20,042
Institutional student loans	19,127	21,987
Due from affiliates	155,096	157,276
Sponsored project receivables	98,222	71,590
Other	145,830	98,673
	<u>966,694</u>	<u>832,645</u>
Less: Allowance for contractual adjustments and doubtful accounts	<u>(319,698)</u>	<u>(280,053)</u>
Total	<u>\$ 646,996</u>	<u>\$ 552,592</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

7. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2021 and 2020 consists of the following:

	Rates at June 30, 2021	Maturity	2021	2020
Missouri Health and Educational Facilities Authority				
\$142,400 of 1996A, B, C and D Series Variable Rate Bonds, due in full	0.11% - 0.13%	September 1, 2030	\$	\$ 132,400
\$88,000 of 2000B and C Series Variable Rate Bonds, due in full	0.01% - 0.03%	March 1, 2040	88,000	88,000
\$25,135 of 2003B Series Variable Rate Bonds, due in full	0.02%	February 15, 2033	25,135	25,135
\$77,495 of 2011C Series Revenue Bonds due serially from November 15, 2012 to November 15, 2037	.75% - 5.06%	November 15, 2037	49,595	51,890
\$200,785 of 2012A Series Revenue Bonds due serially from February 15, 2023 to February 15, 2047	2.39% - 3.69%	February 15, 2047	200,785	200,785
\$150,000 of 2014A Series Revenue Bonds due in full	4.07%	October 15, 2044	150,000	150,000
\$402,920 of 2016A Series Revenue Bonds due in full January 15, 2036 (\$109,300) and January 15, 2046 (\$293,620)	3.47% - 3.65%	January 15, 2036 and 2046	402,920	402,920
\$272,750 of 2016 B Series Revenue Bonds due in full	3.09%	September 15, 2051	272,750	272,750
\$375,000 of 2017 A Series Revenue Bonds, due in full	3.65%	August 15, 2057	375,000	375,000
\$450,000 of 2020 A Series Revenue Bonds, due in full	3.23%	May 15, 2050	450,000	450,000
Other Bonds:				
\$131,435 of 2015A Series Taxable Bonds due in full	3.79%	October 15, 2055	131,435	131,435
Other notes payable			254,953	145,783
Total outstanding notes and bonds payable			2,400,573	2,426,098
Unamortized original issue premiums/discounts and cost of issuance, net			(10,195)	(10,756)
Total			\$ 2,390,378	\$ 2,415,342

Bonds payable are redeemable at the option of the university at various times from 2021 through 2057. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintain a ratio of expendable financial resources to debt of at least 1.25 times. The university is in compliance with this covenant. During 2021 and 2020, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled \$75,531 and \$72,003, respectively.

Maturities on notes and bonds payable for the next five fiscal years are as follows:

2022	\$ 76,658
2023	58,127
2024	2,577
2025	2,627
2026	147,434
Thereafter	2,113,150

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

During fiscal 2021, the university borrowed \$132,400 under a five year term note, the proceeds of which were used to retire the balance of the 1996 MOHEFA bonds. During fiscal 2020, the university issued \$450,000 of Series 2020A Missouri Health and Educational Facilities Authority (MOHEFA) bonds. The bonds bear a fixed rate of 3.23% and will mature on May 15, 2050. The proceeds of these bonds will be used to finance various construction projects.

The university has other lines of credit, which generally expire annually, aggregating \$370,220, of which \$257,695 is available at June 30, 2021. The university expects that these lines of credit will be renewed but can make no assurances.

8. Operating Leases

The university and its consolidated affiliates primarily lease laboratories, office space, and medical offices for educational, research, and patient care purposes under operating leases expiring through 2031. At June 30, 2021, the weighted average remaining lease term was 6.5 years and the weighted average discount rate was 3.05%. Total lease expense of \$28,188 is included in supplies, services, and other on the consolidated statement of activities as of June 30, 2021.

The undiscounted cash flows due by fiscal year related to significant non-cancelable operating leases with initial terms in excess of one year as of June 30, 2021, along with a reconciliation to the discounted amount recorded as of June 30, 2021 were as follows:

2022	\$	23,213
2023		20,549
2024		15,364
2025		12,180
2026		11,586
Thereafter		27,108
Total minimum lease payments	\$	110,000
Less: Imputed interest		(10,334)
Total lease liabilities	\$	99,666

9. Derivative and Other Financial Instruments

The university utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the university uses a third party manager to execute, settle and manage the positions on a non-discretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and quarterly as well as at June 30, with the resulting changes in the values of the contracts either added to or deducted from the university's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

consolidated statements of activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the university invests pose no off-balance sheet risk to the university due to the limited liability structure of the investments. Derivatives are also used to manage operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

10. Functional Expenses

Operating expenses are reported on the consolidated statements of activities in natural categories. Expenses reported by functional categories include allocations of costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs.

Operating expenses by functional and natural classification for the year ended June 30, 2021 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,489,996	\$ 814,548	\$ 75,136	\$ 18,189	\$ 2,397,869
Research	375,891	168,192	54,943	13,278	612,304
Academic Support	176,099		32,063	10,354	218,516
Student Services	43,105	45,323	5,318	2,443	96,189
Institutional Support	124,096	25,399	4,538	799	154,832
Auxiliary Enterprises	19,745	60,265	39,749	26,263	146,022
Other	24,004	11,171	2,078	159	37,412
Total	<u>\$ 2,252,936</u>	<u>\$ 1,124,898</u>	<u>\$ 213,825</u>	<u>\$ 71,485</u>	<u>\$ 3,663,144</u>

Operating expenses by functional and natural classification for the year ended June 30, 2020 are as follows:

Washington University
Notes to Consolidated Financial Statements
June 30, 2021 and 2020

(All amounts in thousands of dollars)

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,437,775	\$ 772,494	\$ 71,378	\$ 18,769	\$ 2,300,416
Research	349,358	158,325	48,975	13,817	570,475
Academic Support	183,997		32,524	10,652	227,173
Student Services	45,838	45,295	6,125	2,710	99,968
Institutional Support	124,582	58,171	5,362	1,037	189,152
Auxiliary Enterprises	19,624	54,167	35,372	23,058	132,221
Other	22,770	15,459	2,237	157	40,623
Total	<u>\$ 2,183,944</u>	<u>\$ 1,103,911</u>	<u>\$ 201,973</u>	<u>\$ 70,200</u>	<u>\$ 3,560,028</u>

11. Commitments and Contingencies

At June 30, 2021 and 2020, the university had outstanding commitments under certain construction contracts in the amount of \$262,844 and \$109,955, respectively.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the consolidated statements of financial position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2021 and 2020, respectively, were \$95,793 and \$91,493. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, consolidated statements of activities, financial position or liquidity of the university.

Washington University

Notes to Consolidated Financial Statements

June 30, 2021 and 2020

(All amounts in thousands of dollars)

12. Retirement Plan

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. The amount of contribution made by the university is based on employee's hire date, age and/or base salary. Vesting provisions are full and immediate. The university's share of the cost of these benefits in 2021 and 2020 was \$71,490 and \$95,214, respectively. During the period July 1, 2020 through October 31, 2020, employer contributions to the plan were temporarily suspended in response to the COVID-19 pandemic. The university provides dependent tuition benefits to qualified retirees. The liability under this plan was \$18,917 and \$22,027 as of June 30, 2021 and 2020, respectively.

13. Agreements with Affiliated Hospitals

The university has affiliation agreements with Barnes Jewish Hospital (BJH), St. Louis Children's Hospital (SLCH), and Barnes Jewish West County Hospital (BJWCH), collectively the Hospitals, which expire December 31, 2027, but may be canceled upon a one-year written notice by either party. These agreements relate to various operating activities of the Hospitals including Orthopedic Center (OC) in Chesterfield, the Siteman Cancer Center – South County, Center for Advanced Medicine (CAM) in South County, BJH Psychiatric Support Center (PSC), and the Children's Specialty Care Center in Town and Country.

Under the terms of the affiliation agreement, the university trains and supervises medical residents and interns and manages certain clinical and research activities of the Hospitals. BJH, SLCH, and BJWCH are responsible for the hospitals and health care delivery facilities and compensate the university for services provided by the university through a fixed annual base payment (adjusted annually for inflation) plus an additional variable payment based on the combined Hospitals' net operating income. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. Payments to the university under affiliation agreements are reported as affiliated hospital revenue on the consolidated statements of activities (see footnote 1). During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of \$17,923 and \$21,507 were received or accrued as gifts on the consolidated statements of activities under the agreement during 2021 and 2020, respectively.

14. Subsequent Events

The university has performed an evaluation of subsequent events through October 4, 2021, which is the date the consolidated financial statements were issued.

Supplemental Information

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Research and Development Cluster					
DEPARTMENT OF DEFENSE					
Advanced Research Projects Agency					
Research and Technology Development	12.910			(237)	-
Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	663,760	-
COVID19-Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	86,712	-
Defense Advanced Research Projects Agency					
Defense Advanced Research Projects Agency	12.RD	Charles River Analytics, Inc	N6600121C4013	73,557	-
Defense Advanced Research Projects Agency	12.RD	Leaflab, LLC	HR00111990036	24,102	-
Defense Advanced Research Projects Agency	12.RD	Raytheon BBN Technologies Corporation	HR001117C0049	124,905	-
Defense Advanced Research Projects Agency	12.RD	Two Six Labs	HR00117C0111	627,607	-
Defense Threat Reduction Agency					
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351			878,956	824,704
Department of Defense					
Department of Defense	12.RD	Cepheid Inc.	W15QKN-16-9-1002	3,720	-
Uniformed Services University Medical Research Projects	12.750	Metis Foundation	HU00011920029	21,322	-
Department of Defense	12.RD	Eccalon LLC	47QTCa18DooDK	131,978	-
Department of Defense	12.RD	North Carolina State University	H9823019D0012 LAS	143,328	-
Department of Defense	12.RD	North Carolina State University	H9823019D0012/0002	51,656	-
Department of the Air Force, Material Command					
Air Force Defense Research Sciences Program	12.800			245,329	-
Air Force Defense Research Sciences Program	12.RD	Nanosonic	FA864920P0983	40,133	-
Air Force Defense Research Sciences Program	12.RD	Raytheon BBN Technologies Corporation	FA875019C0056	166,109	-
Air Force Defense Research Sciences Program	12.RD	UES, Inc.	FA865019D6109	27,512	-
Air Force Defense Research Sciences Program	12.800	Princeton University	FA95502010241	238,501	-
Air Force Defense Research Sciences Program	12.800	Vanderbilt University	FA95501810126	73,575	-
Department of the Navy, Office of the Chief of Naval Research					
Applied Research and Exploratory Development	12.RD			(132)	-
Basic and Applied Scientific Research	12.300			1,531,098	169,560
Basic and Applied Scientific Research	12.300	University of California, Davis	N000141712961	304,797	-
Basic and Applied Scientific Research	12.300	University of Southern California	N000141812632	118,494	-
U.S. Army Material Command					
Military Medical Research and Development	12.RD	Arizona State University	W911NF19C0039	50,000	-
Basic Scientific Research	12.431			265,100	39,445
Basic Scientific Research	12.431	Georgia Institute of Technology	W911W61720002	40,865	-
Basic Scientific Research	12.431	Leonard Wood Institute	W911NF1420034	57,531	-
Basic Scientific Research	12.431	University of Michigan	W911NF1810208	59,180	-
Basic Scientific Research	12.431	University of Minnesota	W911NF1810240	262,525	-
Basic Scientific Research	12.431	Virginia Tech	W911NF2010141	31,606	-
U.S. Army Medical Command					
Military Medical Research and Development	12.RD			4,274,966	819,588
Military Medical Research and Development	12.RD	SARC	W81XWH1710695	13,887	-
Military Medical Research and Development	12.RD	University of Maryland, Baltimore	W81XWH1710668	(1,793)	-
Military Medical Research and Development	12.420			10,331,556	692,105
Military Medical Research and Development	12.420	Brigham and Women's Hospital	W81XWH1510269	14,475	-
Military Medical Research and Development	12.420	Health Research Inc.	WBLXWH1910674	5,260	-
Military Medical Research and Development	12.420	Idibiologics	W81XWH1910405	54,037	-
Military Medical Research and Development	12.420	Johns Hopkins University	W81XWH1810815	4,462	-
Military Medical Research and Development	12.420	Northern California Institute for Research and Education	W81XWH1310259	28,221	-
Military Medical Research and Development	12.420	St. Louis College of Pharmacy	W81XWH1610235	618	-
Military Medical Research and Development	12.420	St. Louis University	W81XWH1910117	24,080	-
Military Medical Research and Development	12.420	St. Louis University	W81XWH2010241	143,322	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1720037	2,064	-
Military Medical Research and Development	12.420	University of Minnesota	W81XWH1710633	3,366	-
Military Medical Research and Development	12.420	University of Missouri	W81XWH1520037	37,259	-
Military Medical Research and Development	12.420	University of Pittsburgh	W81XWH1720073	852	-
Military Medical Research and Development	12.420	University of South Carolina	W81XWH1920051	4,457	-
Military Medical Research and Development	12.420	Veterans Research and Education Foundation of St. Louis	W81XWH1810548	392,203	-
Military Medical Research and Development	12.420	Veterans Research and Education Foundation of St. Louis	W81XWH2010785	26,914	-
TOTAL DEPARTMENT OF DEFENSE				21,703,795	2,545,402

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
DEPARTMENT OF EDUCATION					
Office of Postsecondary Education					
Graduate Assistance in Areas of National Need	84.200			30,406	-
Office of Special Education and Rehabilitative Services					
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325			368,857	-
TOTAL DEPARTMENT OF EDUCATION				399,263	-
DEPARTMENT OF ENERGY					
Department of Energy					
Office of Science Financial Assistance Program	81.049			3,784,317	743,463
Office of Science Financial Assistance Program	81.049	Aerosol Dynamics	DESC0013103	56,070	-
Office of Science Financial Assistance Program	81.049	Aerosol Dynamics	DESC0020495	43,933	-
Office of Science Financial Assistance Program	81.049	Georgia Tech	DESC0012577	30,637	-
Office of Science Financial Assistance Program	81.049	Michigan State University	DESC0013617	129,680	-
Office of Science Financial Assistance Program	81.049	TDA Research, Inc	DE-SC0018502	7,565	-
Renewable Energy Research and Development	81.087			253,113	264,145
Renewable Energy Research and Development	81.087	West Virginia Research Corporation	DEP10000017	184,993	-
Fossil Energy Research and Development	81.089			470,238	19,607
Fossil Energy Research and Development	81.089	Linde LLC	DEFE0031592	147,696	-
Stewardship Science Grant Program	81.112			305,886	-
Stewardship Science Grant Program	81.112	Texas A&M University	DENA0003841	73,897	-
Advanced Research Projects Agency - Energy	81.135			475,423	-
Department of Energy	81.RD	Battelle Memorial Institute	394636	170,046	-
Department of Energy	81.RD	Fermi National Accelerator Lab	DEAC0207CH11359	133,884	-
Department of Energy	81.RD	Lawrence Livermore National Laboratory	DEAC5207NA27344	53,830	-
Department of Energy	81.RD	TRIAD National Security, Los Alamos National Laboratory	89233218CNA000001	91,874	-
Department of Energy	81.RD	University of California, Lawrence Berkley National Laboratory	DEAC0205CH11231	225,088	-
TOTAL DEPARTMENT OF ENERGY				6,638,170	1,027,215
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Children and Families					
Healthy Marriage Promotion and Responsible Fatherhood Grants	93.086	Father's Support Center St. Louis	HHS2015ACFOFAFK0993	54,374	-
Administration for Children and Families	93.RD	Vision for Children	PACTSTL	103,317	-
Administration for Community Living					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433			364,898	54,687
Alzheimer's Disease Initiative	93.763	Memory Home Care Solutions	90ALGG00210100	10,422	-
ACL Assistive Technology State Grants for Protection and Advocacy	93.843	Tulane University	5R01HL12242607	74,046	-
Agency for Healthcare Research and Quality					
Research on Healthcare Costs, Quality and Outcomes	93.226			1,845,363	358,358
Research on Healthcare Costs, Quality and Outcomes	93.226	Indiana University	R01HS02541102	(549)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Iowa	5R01HS02672402	86,435	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Maryland, Baltimore	5R01HS02545602	(149)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Maryland, Baltimore	5R01HS02545604	160,675	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Pennsylvania	1R01HS02742801	57,806	-
Research on Healthcare Costs, Quality and Outcomes	93.RD	University of New Mexico	75Q80120C00003	37,946	-
Centers for Disease Control					
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084			604,151	284,420
COVID19-Prevention of Disease, Disability, and Death by Infectious Diseases	93.084			597,447	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Duke University	6U54CK0004830401	22,108	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	North Carolina State University	1U01CK0005870100	167,479	-
COVID19-Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	North Carolina State University	1U01CK00058701	180,957	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	6U54CK00048102	794	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University of Pennsylvania	5U54CK00048502	(3,232)	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135			743,751	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135			8,408	-
Occupational Safety and Health Program	93.262			472,173	207,436
Occupational Safety and Health Program	93.262	Center For Construction Research & Training	U60OH009762	120,070	-
Occupational Safety and Health Program	93.262	Center For Construction Research & Training	U60OH00976211	147,505	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Occupational Safety and Health Program	93.262	University of California, San Diego	1R01OH11661	149,873	-
Occupational Safety and Health Program	93.262	University of Colorado	5U19OH01122704	5,568	-
Occupational Safety and Health Program	93.262	University of Colorado	6U19OH0112270501	14,415	-
Occupational Safety and Health Program	93.262	University of Iowa	5U10OH00886814	36,109	-
Occupational Safety and Health Program	93.262	University of Iowa	5U19OH00886815	300,664	-
Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283			636,379	248,201
Early Hearing Detection and Intervention Information System Surveillance Program	93.314	University of Kansas Medical Center	5U13HS338780200	3,330	-
Childhood Obesity Research Demonstration	93.349			673,552	198,544
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	1NU58DP00651002	68,809	-
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	5NU58DP00651003	110,355	-
Capacity Building Assistance for High-Impact HIV Prevention	93.834			636,410	112,826
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978			632,711	42,432
Centers for Disease Control	93.RD			(6,676)	-
Centers for Disease Control	93.RD	Rainmakers Strategic Solutions		5,904	-
Centers for Disease Control	93.RD	St. Louis County	DP18-1817	114,248	56,718
COVID19-Centers for Disease Control	93.RD	Task Force for Global Health	NU38OT000316	27,757	-
Food and Drug Administration					
Food and Drug Administration_Research	93.103	Columbia University	5R01FD00574503	29,715	-
Health Resources and Services Administration					
Grants to Increase Organ Donations	93.134	Johns Hopkins University	5R39OT311030300	10,363	-
Rural Health Research Centers	93.155	University of Iowa	5U1CRH204191100	28,744	-
Rural Health Research Centers	93.155	University of Iowa	6U1CRH204191001	18,805	-
IMMED Office of the Secretary of Health and Human Services					
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.360	Integrated Biotherapeutics Inc	IDSEP160030-02	67,857	-
National Institutes of Health					
Environmental Health	93.113			3,261,157	637,822
Environmental Health	93.113	Baylor College of Medicine	5U01ES02671905	(336)	-
Environmental Health	93.113	Colorado State University	1R01ES03093701	120,591	-
Environmental Health	93.113	Johns Hopkins University	5R01ES02696102	55,715	-
Environmental Health	93.113	University of Louisville	5R01ES02984603	77,772	-
Oral Diseases and Disorders Research	93.121			1,116,052	165,686
Oral Diseases and Disorders Research	93.121	Kaiser Foundation	1R01DE02829601A1	117,593	-
Oral Diseases and Disorders Research	93.121	University of Alabama, Birmingham	3U01DE02872702S1	150,344	-
Oral Diseases and Disorders Research	93.121	University of Illinois, Chicago	3U19DE02871702S1	123,468	-
Oral Diseases and Disorders Research	93.121	University of Louisville	7R01DE02647104	20,167	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	5P42ES02371604	71,828	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	5P42ES02371605	17,608	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	P42ES023716	(43,937)	-
Human Genome Research	93.172			14,165,371	1,170,636
Human Genome Research	93.172	California Institute of Technology	U24HG002223	36,053	-
Human Genome Research	93.172	Geisinger Clinic	5R01HG00967102	16,688	-
Human Genome Research	93.172	Harvard University	5U01HG00753006	44,693	-
Human Genome Research	93.172	New York Genome Center	5UM1HG00890104	46,211	-
Human Genome Research	93.172	Stanford University	5UM1HG00944204	146,008	-
Human Genome Research	93.172	The Broad Institute	5U24HG01026203	75,413	-
Human Genome Research	93.172	The Broad Institute	U24HG01026202	671	-
Human Genome Research	93.172	University of California, Santa Cruz	1R13HG01119701	12,700	-
Human Genome Research	93.172	University of California, Santa Cruz	1U01HG01097101	124,855	-
Human Genome Research	93.172	University of California, Santa Cruz	5U01HG01097102	451,761	-
Human Genome Research	93.172	Vanderbilt University	5RM1HG00903404	(12,186)	-
Research Related to Deafness and Communication Disorders	93.173			6,482,462	617,755
Research Related to Deafness and Communication Disorders	93.173	Boystown National Research Hospital	1R01DC018333001A1	2,976	-
Research Related to Deafness and Communication Disorders	93.173	Cincinnati Children's Hospital Medical Center	1R01DC01786701A1	11,396	-
Research Related to Deafness and Communication Disorders	93.173	Clear	1R43DC01824701	19,570	-
Research Related to Deafness and Communication Disorders	93.173	East Carolina University	5R01DC01770202	24,692	-
Research Related to Deafness and Communication Disorders	93.173	Father Flanagan's Boys Home	5R01DC01538505	200,321	-
Research Related to Deafness and Communication Disorders	93.173	Northwestern University	5R01DC01627302	(3,130)	-
Research Related to Deafness and Communication Disorders	93.173	Ohio State University	U01DC018920	59,619	-
Research Related to Deafness and Communication Disorders	93.173	University of Alabama	5R01DC01598003	156,716	-
Research Related to Deafness and Communication Disorders	93.173	University of Iowa	1R01DC01848801A1	55,042	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	5P01AG05144302	128,288	84,301
Research Related to Deafness and Communication Disorders	93.173	University of Pittsburgh	2R01HD07951206A1	32,023	-
Research Related to Deafness and Communication Disorders	93.173	University of Pittsburgh	2R01DC01304806A1	53,613	-
Research Related to Deafness and Communication Disorders	93.173	University of Southern California	5R01DC01774102	86,685	-
Research Related to Deafness and Communication Disorders	93.173	University of Utah	2R01DC01131108	22,221	-
Research Related to Deafness and Communication Disorders	93.173	Vanderbilt University	2RM1HG00903405	59,451	-
Research and Training in Complementary and Integrative Health	93.213			2,149,771	84,489
Research and Training in Complementary and Integrative Health	93.213	Yale University	1R01AT01141901	11,730	-
National Center on Sleep Disorders Research	93.233			285,906	-
National Center on Sleep Disorders Research	93.233	Johns Hopkins University	3U01HL15056801S1	17,079	-
Mental Health Research Grants	93.242			32,793,431	7,359,685
Mental Health Research Grants	93.242	Centre for Addictioen and Mental Health	5R01MH11831103	13,984	-
Mental Health Research Grants	93.242	Chapman University	5P50MH09688908	9,155	-
Mental Health Research Grants	93.242	Chapman University	2P50MH09688906A1	24,407	-
Mental Health Research Grants	93.242	Columbia University	1R01MH12231901A1	4,439	-
Mental Health Research Grants	93.242	Columbia University	1R01MH12059701	15,598	-
COVID19-Mental Health Research Grants	93.242	Columbia University	R01MH120597	15,605	-
Mental Health Research Grants	93.242	Duke University	5R01MH11048805	1,545	-
Mental Health Research Grants	93.242	Emory University	1R01MH11469203	125,757	-
Mental Health Research Grants	93.242	Emory University	5R01MH11469205	12,768	-
Mental Health Research Grants	93.242	Emory University	5R01MH11828502	14,084	-
Mental Health Research Grants	93.242	Geisinger Clinic	3U01MH11970502S1	19,536	-
Mental Health Research Grants	93.242	Geisinger Clinic	5U01MH11970502	382,788	-
Mental Health Research Grants	93.242	Indiana University	5R01MH10846704	(5,194)	-
Mental Health Research Grants	93.242	Kitware, Inc.	1R41MH11884501	3,123	-
Mental Health Research Grants	93.242	Kitware, Inc.	3R41MH11884502S1	39,716	-
Mental Health Research Grants	93.242	NeuroLux, Inc.	2R42HM11652502	40,200	-
Mental Health Research Grants	93.242	NeuroLux, Inc.	2R44MH11494403A1	83,079	-
Mental Health Research Grants	93.242	New York University	5P50MH11366202	219,066	-
Mental Health Research Grants	93.242	New York University	3P50MH113662-01A1S1	(6,408)	-
Mental Health Research Grants	93.242	Northwestern University	1R01M12187701	227,409	-
Mental Health Research Grants	93.242	Northwestern University	1R01M12187701A1	196,127	-
Mental Health Research Grants	93.242	Nous Imaging	1R44MH12127601A1	71,671	-
Mental Health Research Grants	93.242	Nous Imaging	1R44MH12206601	(24,140)	-
Mental Health Research Grants	93.242	Nous Imaging	1R44MH12456701	74,228	-
Mental Health Research Grants	93.242	Nous Imaging	4R44MH12206602	80,806	-
Mental Health Research Grants	93.242	Research Foundation Mental Hygiene	5P50MH11584304	27,171	-
Mental Health Research Grants	93.242	Research Foundation Mental Hygiene	5P50MH11584303	25,671	-
Mental Health Research Grants	93.242	Rutgers University	2U24MH06845718	10,762	-
Mental Health Research Grants	93.242	Rutgers University	5U524MH06845719	977	-
Mental Health Research Grants	93.242	St. Louis College of Pharmacy	5R01MH09276911	131,777	-
Mental Health Research Grants	93.242	St. Louis College of Pharmacy	R01MH09276911	36,150	-
Mental Health Research Grants	93.242	The Miriam Hospital	5R01MH11465705	131,184	-
Mental Health Research Grants	93.242	Universidad De O'Higgins	1U01MH11550201	49,539	-
Mental Health Research Grants	93.242	University of Alabama, Birmingham	5R01MH11678903	13,305	-
Mental Health Research Grants	93.242	University of Alabama, Birmingham	5R34MH12110302	28,538	-
Mental Health Research Grants	93.242	University of California, Los Angeles	5R01MH10002713	283,850	-
Mental Health Research Grants	93.242	University of California, Los Angeles	5R01MH12146202	122,152	-
Mental Health Research Grants	93.242	University of California, San Diego	5R01MH10734505	18,185	-
Mental Health Research Grants	93.242	University of California, San Diego	5R01MH11821702	12,785	-
Mental Health Research Grants	93.242	University of Illinois, Chicago	1R61MH11923701A1	35,282	-
Mental Health Research Grants	93.242	University of Maryland, Baltimore	1RF1MH12316301A1	1,060	-
Mental Health Research Grants	93.242	University of Minnesota	5R01MH09677309	455,411	-
Mental Health Research Grants	93.242	University of Minnesota	5R01MH11696104	21,329	-
Mental Health Research Grants	93.242	University of Missouri, St. Louis	5R01MH10855904	113,505	-
Mental Health Research Grants	93.242	University of North Carolina at Chapel Hill	5U01MH11092504	1,096	-
Mental Health Research Grants	93.242	University of North Carolina at Chapel Hill	5U01MH11092505	73,632	-
Mental Health Research Grants	93.242	University of South Carolina	7R01MH10638802	27,055	-
Mental Health Research Grants	93.242	University of Washington	5R01MH10854804	7,833	-
Mental Health Research Grants	93.242	University of Washington	5R01MH11152004	(609)	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Mental Health Research Grants	93.242	Yale University	1U01MH12463901	137,564	-
Mental Health Research Grants	93.242	Yale University	5R01MH10859003	8,933	-
Mental Health Research Grants	93.242	Yale University	5R01MH11274604	56,179	-
Alcohol Research Programs	93.273			2,132,754	249,473
Alcohol Research Programs	93.273	Johns Hopkins University	5R01AA02348305	28,599	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	2U10AA00840131	345,329	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	5U10AA00840132	845,300	-
Alcohol Research Programs	93.273	RTI International	1R01AA02704901A1	18,648	-
Alcohol Research Programs	93.273	University of California, San Francisco	5R34AA02798302	20,416	-
Alcohol Research Programs	93.273	University of Illinois, Urbana-Champaign	7R01AA02410303	14,834	-
Alcohol Research Programs	93.273	University of Missouri	5R01AA02782402	59,811	-
Alcohol Research Programs	93.273	Virginia Commonwealth University	1R01AA02806401A1	3,934	-
Drug Abuse and Addiction Research Programs	93.279			12,982,233	2,329,902
COVID19-Drug Abuse and Addiction Research Programs	93.279			80,207	-
Drug Abuse and Addiction Research Programs	93.279	Benton Technologies	1R43DA04697401	4,064	-
Drug Abuse and Addiction Research Programs	93.279	Denver Health	3U01DA03836005S4	14,711	-
Drug Abuse and Addiction Research Programs	93.279	Duke University	7R01DA04298502	5,108	-
Drug Abuse and Addiction Research Programs	93.279	Intra-Cellular Therapies Inc.	UG3DA047699	76,030	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	5R01DA04209404	13,114	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	5RF1AG05074502	72,635	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	5R21DA4779502	8,298	-
Drug Abuse and Addiction Research Programs	93.279	McClean Hospital	3UG2DA01583118S9	90,211	-
Drug Abuse and Addiction Research Programs	93.279	McClean Hospital	5UG1DA01583118S9	62,968	-
Drug Abuse and Addiction Research Programs	93.279	Ohio State University	R01DA053028	5,918	-
Drug Abuse and Addiction Research Programs	93.279	Rissana LLC	1R24DA05023201	25,966	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	1R01DA04401401	67,512	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	5R01DA04209003	129,301	-
Drug Abuse and Addiction Research Programs	93.279	St. Louis College of Pharmacy	5R21DA04865002	65,033	-
Drug Abuse and Addiction Research Programs	93.279	St. Louis University	5R01DA04381103	28,987	-
Drug Abuse and Addiction Research Programs	93.279	University of California, San Diego	3U24DA04114706S2	6,917	-
Drug Abuse and Addiction Research Programs	93.279	University of Chicago	5UH3DA04482904	6,855	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112004	(31)	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112005	(902)	-
Drug Abuse and Addiction Research Programs	93.279	University of North Carolina, Chapel Hill	5R01DA04787604	50,298	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			7,210,918	111,357
COVID19-Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			395,734	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Albany Research Institute	NS108916	60,679	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	5R01EB02925902	149,035	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Florida International University	5R01EB02758402	6,471	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Georgia Tech	1R01EB02985201	36,288	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Illinois Institute of Technology	1R01EB02980001A1	73,768	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Kitware, Inc.	5R01EB02139602	23,180	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	New York Medical College	5R01EB02831902	5,022	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Connecticut	1U01EB02889801	9,365	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Connecticut	1U01HL15634901	90,388	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Delaware	5R01EB02757703	202,474	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois, Urbana-Champaign	7R01EB02304504	70,754	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois, Urbana-Champaign	7R01EB02060404	9,188	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois, Urbana-Champaign	5R01EB02865203	53,053	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Massachusetts	5U01EB02195604	1,295	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Worcester Polytechnic Institute	5R01EB00475908	4	-
Minority Health and Health Disparities Research	93.307			783,886	124,035
Minority Health and Health Disparities Research	93.307	Northwestern University	5R01MD01174904	53,427	-
Minority Health and Health Disparities Research	93.307	University of Pittsburgh	5R01MD000911805	(2,995)	-
Minority Health and Health Disparities Research	93.307	University of Virginia	2R01MD00770206A1	5,296	-
Trans-NIH Research Support	93.310			3,042,467	67,814
COVID19-Trans-NIH Research Support	93.310			447,459	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital	5UGOD02326802	315,016	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital	5UH3OD02326804	64,905	-
Trans-NIH Research Support	93.310	California Institute of Technology	7R01CA18656705	(496)	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Trans-NIH Research Support	93.310	Duke University	3UCOD02337504S1	23,011	-
Trans-NIH Research Support	93.310	Duke University	5U2COD02337503	15,011	-
Trans-NIH Research Support	93.310	Duke University	5U2COD02337504	1,427	-
Trans-NIH Research Support	93.310	Harvard University	5U01HG00753007	48,737	-
Trans-NIH Research Support	93.310	Stanford University	5U54HG01042602	146,565	-
Trans-NIH Research Support	93.310	University of California, San Diego	1UM1HG01158501	79,122	-
Trans-NIH Research Support	93.310	University of California, San Diego	5U54HL14560802	19	-
Trans-NIH Research Support	93.310	University of California, San Diego	5U54HL14560803	228,163	-
Trans-NIH Research Support	93.310	University of North Carolina at Chapel Hill	5U24DK11620403	227,104	-
Trans-NIH Research Support	93.310	University of North Carolina at Chapel Hill	5U24DK11620404	154,567	-
Trans-NIH Research Support	93.310	University of North Carolina at Chapel Hill	5U24DK1162040403	11,419	-
Trans-NIH Research Support	93.310	University of Wisconsin, Madison	5UH3OD02328204	398,145	-
National Center for Advancing Translational Sciences	93.350			12,612,357	695,005
National Center for Advancing Translational Sciences	93.350	Boston Children's Hospital	5U01TR00262302	36,268	-
National Center for Advancing Translational Sciences	93.350	Duke University	5U01TR00180303	918	-
National Center for Advancing Translational Sciences	93.350	Dystonia Medical Research Foundation	U54TR001456	9,415	-
National Center for Advancing Translational Sciences	93.350	Oregon Health And Science University	5U24TR00230603	3,273	-
National Center for Advancing Translational Sciences	93.350	Oregon Health And Science University	5U24TR00230604	401,693	-
National Center for Advancing Translational Sciences	93.350	Precision Virologics	7R41TR00186902	46,890	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh	5UL1TR00185702	36,657	-
National Center for Advancing Translational Sciences	93.350	Vanderbilt University Medical Center	5U01TR00239802	95,419	-
National Center for Advancing Translational Sciences	93.350	Vanderbilt University Medical Center	U01TR002398	(13,155)	-
Research Infrastructure Programs	93.351			3,521,683	213,487
COVID19-Research Infrastructure Programs	93.351			122,441	-
Research Infrastructure Programs	93.351	Cornell University	2P40OD096416	13,073	-
Research Infrastructure Programs	93.351	Cornell University	5P40OD01096416	9,279	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353			5,810,144	172,179
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Duke University	1U2CCA23325401	103,890	-
Nursing Research	93.361			1,774,127	517,599
Nursing Research	93.361	Barnes Jewish Hospital	1R15NR01682801A1	6	-
Nursing Research	93.361	St. Louis University	3R21NR017978-01A1S1	4,117	-
Nursing Research	93.361	University of California, Irvine	R01NR105591	2,678	-
Nursing Research	93.361	University of Colorado, Denver	5U2CNR01463708	21,166	-
Nursing Research	93.361	University of Pennsylvania	5R01NR01221308	94,665	-
Cancer Cause and Prevention Research	93.393			11,042,415	1,539,901
COVID19-Cancer Cause and Prevention Research	93.393			141,240	-
Cancer Cause and Prevention Research	93.393	Baylor University	1U19CA20365402	38,711	-
Cancer Cause and Prevention Research	93.393	Baylor University	5U19CA20365405	8,108	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5U01CA19556805	31,282	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5U01CA19556806A1	292	-
Cancer Cause and Prevention Research	93.393	MD Anderson Cancer Center	5R01CA22564703	21,474	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan Kettering Cancer Research Center	5R01CA22323103	92,904	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan Kettering Cancer Research Center	5R01CA22323104	30,261	-
Cancer Cause and Prevention Research	93.393	Northwestern University	5R01CA21843603	1,354	-
Cancer Cause and Prevention Research	93.393	Northwestern University	5R01CA21843604	29,813	-
Cancer Cause and Prevention Research	93.393	Northwestern University	R01CA218436	1,191	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5P01CA10073013	(820)	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5P01CA10073015	2,300	-
Cancer Cause and Prevention Research	93.393	Quantitative Radiology Solutions	2R42CA19973502	31,261	-
Cancer Cause and Prevention Research	93.393	Research Foundation For The State University of New York	5R01CA19735104	683	-
Cancer Cause and Prevention Research	93.393	St. Jude Children's Research Institute	3U01CA19554706S1	63,311	-
Cancer Cause and Prevention Research	93.393	Stanford University	5R01CA19369405	30,011	-
Cancer Cause and Prevention Research	93.393	The Hospital for Sick Children	5R01CA25111202	2,926	-
Cancer Cause and Prevention Research	93.393	The Hospital for Sick Children	R01CA25111201	9,494	-
Cancer Cause and Prevention Research	93.393	University of California, Berkeley	3P01CA09258419S1	208,158	-
Cancer Cause and Prevention Research	93.393	University of California, San Francisco	5R01CA185687	(2,219)	-
Cancer Cause and Prevention Research	93.393	University Of Connecticut	5R01CA22025404	27,336	-
Cancer Cause and Prevention Research	93.393	University of Iowa	U1CRH204190	87,896	-
Cancer Cause and Prevention Research	93.393	University of Iowa	5R01CA19324905	67,814	-
Cancer Cause and Prevention Research	93.393	University of Massachusetts, Worcester	5R01CA22501802	37,002	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Cancer Cause and Prevention Research	93-393	University of Missouri	5R01CA20399904	11,044	-
Cancer Cause and Prevention Research	93-393	University of North Carolina at Chapel Hill	5P01CA22559703	582,269	12,194
Cancer Cause and Prevention Research	93-393	University of North Carolina, Charlotte	3U01CA23550703S1	4,759	-
Cancer Cause and Prevention Research	93-393	University of Utah	5U01CA20611004	61,724	-
Cancer Cause and Prevention Research	93-393	Vanderbilt University	5R01CA220050503	27,022	-
Cancer Cause and Prevention Research	93-393	Wake Forest University	5R01CA22607803	198,904	-
Cancer Detection and Diagnosis Research	93-394			8,940,761	1,896,230
COVID19-Cancer Detection and Diagnosis Research	93-394			142,264	-
Cancer Detection and Diagnosis Research	93-394	Lasmed LLC	1R43CA20679601A1	697	-
Cancer Detection and Diagnosis Research	93-394	New York University School of Medicine	5U24CA210972	105,717	-
Cancer Detection and Diagnosis Research	93-394	New York University School of Medicine	5U24CA21097204	7,313	-
Cancer Detection and Diagnosis Research	93-394	Princeton University	5U24CA21100004	(525)	-
Cancer Detection and Diagnosis Research	93-394	Princeton University	5U24CA21100005	8,874	-
Cancer Detection and Diagnosis Research	93-394	University of Arkansas Health Sciences	5U01CA18701305	1,316	-
Cancer Detection and Diagnosis Research	93-394	University of Arkansas	U24CA215109	17,690	-
Cancer Detection and Diagnosis Research	93-394	University of California, Los Angeles	5R01CA24630402	20,960	-
Cancer Detection and Diagnosis Research	93-394	University of California, San Francisco	5R01CA21214805	215,117	-
Cancer Detection and Diagnosis Research	93-394	University of Illinois, Urbana-Champaign	1R01CA23387301A1	56,876	-
Cancer Detection and Diagnosis Research	93-394	University of Miami	5U01CA2336303	182,164	-
Cancer Detection and Diagnosis Research	93-394	University of Miami	5U01CA2336302	25,761	-
Cancer Detection and Diagnosis Research	93-394	University of Pennsylvania	1R01CA258717-01	4,205	-
Cancer Detection and Diagnosis Research	93-394	University of Pennsylvania	5R01CA20426104	3,806	-
Cancer Detection and Diagnosis Research	93-394	University of Pennsylvania	5R01CA20426105	22,444	-
Cancer Detection and Diagnosis Research	93-394	Vanderbilt University Medical Center	5U01CA15266210	19,171	-
Cancer Detection and Diagnosis Research	93-394	Vanderbilt University Medical Center	5U24CA08636819	24,737	-
Cancer Treatment Research	93-395			13,424,592	1,114,497
Cancer Treatment Research	93-395	Accuronix Therapeutics	1R41CA23985301A1	69,613	-
Cancer Treatment Research	93-395	American College Of Radiology	1U24CA18080307IROC	38,091	-
Cancer Treatment Research	93-395	Children's Hospital Of Philadelphia	2U10CA180866	50,629	-
Cancer Treatment Research	93-395	Children's Hospital Of Philadelphia	5R01CA21199602	1,123	-
Cancer Treatment Research	93-395	Children's Hospital Of Philadelphia	5UM1CA22882302	74,236	-
Cancer Treatment Research	93-395	Duke University	3UM1CA186704-04S1	1,071	-
Cancer Treatment Research	93-395	Duke University	3UM1CA18670405S1	8,728	-
Cancer Treatment Research	93-395	Ecog-Acrin Medical Research Foundation	5U01CA18082008	7,933	-
Cancer Treatment Research	93-395	Ecog-Acrin Medical Research Foundation	5U10CA18082008	3,578	-
Cancer Treatment Research	93-395	Ecog-Acrin Medical Research Foundation	U10CA18082006	26,290	-
Cancer Treatment Research	93-395	Emmes	2UM1CA12194714	120,674	-
Cancer Treatment Research	93-395	Johns Hopkins University	5UM1CA13744309	13,498	-
Cancer Treatment Research	93-395	Massachusetts General Hospital	5U01NS9366302	295	-
Cancer Treatment Research	93-395	Medical Guidance Systems	1R41CA23302001A1	70,503	-
Cancer Treatment Research	93-395	Medical Guidance Systems	2R44CA21068702A1	234,508	-
Cancer Treatment Research	93-395	NRG Oncology Foundation	1U10CA18086001	22,576	-
Cancer Treatment Research	93-395	NRG Oncology Foundation	2U10CA180868-06	93,079	6,776
Cancer Treatment Research	93-395	NRG Oncology Foundation	5U10CA18086805	9	-
Cancer Treatment Research	93-395	NRG Oncology Foundation	5U10CA18086807	9,860	-
Cancer Treatment Research	93-395	NRG Oncology Foundation	5U10CA18086808	16,699	-
Cancer Treatment Research	93-395	NRG Oncology Foundation	U10CA180868	(55)	-
Cancer Treatment Research	93-395	Protexase	1R43CA24394101A1	17,755	-
Cancer Treatment Research	93-395	Sloan Kettering Institute	1U01CA23844401A1	32,588	-
Cancer Treatment Research	93-395	St. Jude Children's Research Institute	1U01CA24657001A1	6,078	-
Cancer Treatment Research	93-395	University of California, Los Angeles	UMCA121947	732	-
Cancer Treatment Research	93-395	University of Minnesota	5P01CA11141214	72,586	-
Cancer Treatment Research	93-395	University of Rochester	1R01CA21489001A1	30,131	-
Cancer Treatment Research	93-395	University of Texas M.D. Anderson	1R01CA23562201	218,476	-
Cancer Treatment Research	93-395	Vanderbilt University	5R01CA21404305	16,451	-
Cancer Treatment Research	93-395	Yale University	2UM1CA18668906	72,955	-
Cancer Treatment Research	93-395	Yale University	5UM1CA18668907	38,672	-
Cancer Biology Research	93-396			9,003,961	327,936
Cancer Biology Research	93-396	Case Western Reserve University	1P01CA24570501	1,955	-
Cancer Biology Research	93-396	Case Western Reserve University	1P01CA24570501A1	48,231	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Cancer Biology Research	93.396	Kaiser Permanente	5UM1CA22194003	40,975	-
Cancer Biology Research	93.396	North Carolina Central University	1R01CA24423601	181,525	-
Cancer Biology Research	93.396	Ohio State University	2P01CA10073016A1	373,195	-
Cancer Biology Research	93.396	Ohio State University	P01CA100730	335,502	-
Cancer Biology Research	93.396	University of Virginia	5R21CA21272604	18,419	-
Cancer Biology Research	93.396	University of Virginia	5R21CA23185303	3,307	-
Cancer Center Support Grants	93.397			10,680,556	453,303
Cancer Center Support Grants	93.397	Case Western Reserve University	5U54CA16306009	60,646	-
Cancer Center Support Grants	93.397	Case Western Reserve University	U54CA16306009	35,417	-
Cancer Center Support Grants	93.397	John Hopkins University	U54CA210173	102,224	-
Cancer Research Manpower	93.398			5,435,616	-
Cancer Control	93.399	Alliance for Center in Oncology Foundation	2UG1CA18982306	6,962	-
Cancer Control	93.399	Children's Hospital Of Philadelphia	2UG1CA1899506	72,965	-
Cancer Control	93.399	NRG Oncology Foundation	3UG1CA18986706S2	147,334	-
Cardiovascular Diseases Research	93.837			23,849,324	1,345,955
Cardiovascular Diseases Research	93.837	Brigham & Women's Hospital	5P50HL11234905	(11,476)	-
Cardiovascular Diseases Research	93.837	Children's Hospital Of Philadelphia	1R01HL14761601	793	-
Cardiovascular Diseases Research	93.837	Children's Hospital Of Philadelphia	5R01HL13154405	18,362	-
Cardiovascular Diseases Research	93.837	Duke University	U10HL084904	55,615	-
Cardiovascular Diseases Research	93.837	Emory University	2R01HL12239206A1	3,691	-
Cardiovascular Diseases Research	93.837	Emory University	5R01HL12239207	36,892	-
Cardiovascular Diseases Research	93.837	Emory University	5U01HL12856602	(3,625)	-
Cardiovascular Diseases Research	93.837	Emory University	5U01HL12856606	(1,915)	-
Cardiovascular Diseases Research	93.837	Etiometry Inc	2R44HL173405	48,322	-
Cardiovascular Diseases Research	93.837	I-Cordis LLC	1R43HL14583301A1	30,582	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	2004688628	(2,681)	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5U01HL09681210	95,120	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center, Inc	5R01HL0677317	49,498	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center, Inc	7R01HL0677316	55,373	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL13864604	71,630	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL12333608	22,394	-
Cardiovascular Diseases Research	93.837	Medical College of Wisconsin	5R01HL12558003	(6,966)	-
Cardiovascular Diseases Research	93.837	Medical College of Wisconsin	5R01HL12558004	18,389	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U24HL138660	605	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	4U10HL06029416	645	-
Cardiovascular Diseases Research	93.837	New England Research Institutes	1U24HL13569101	14,767	-
Cardiovascular Diseases Research	93.837	New England Research Institutes	5U24HL13569102	25,375	-
Cardiovascular Diseases Research	93.837	Northwestern University	5R01HL13694203	39,769	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	2R01HL04509529A1	151,955	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL12885703	(20,034)	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL12885704	34,818	-
Cardiovascular Diseases Research	93.837	Ohio State University	5UH3HL14014403	35,850	-
Cardiovascular Diseases Research	93.837	Ohio State University	1R01HL14858101A1	7,198	-
Cardiovascular Diseases Research	93.837	Research Foundation For The State University of New York	5U01HL13155205	390,463	-
Cardiovascular Diseases Research	93.837	Sentiar, Inc	5R44HL14089603	24,579	-
Cardiovascular Diseases Research	93.837	St. Louis University	5R01HL12542404	7,778	-
Cardiovascular Diseases Research	93.837	University of Alabama	5U01HL12033806	6,886	-
Cardiovascular Diseases Research	93.837	University of Alabama, Birmingham	1R01HL14914501	295	-
Cardiovascular Diseases Research	93.837	University of Alabama, Birmingham	5R01HL14914502	39,707	-
Cardiovascular Diseases Research	93.837	University of California, Davis	3UH3HL14180004S1	199,405	-
Cardiovascular Diseases Research	93.837	University of California, Davis	4UG3HL14180003	45,617	-
Cardiovascular Diseases Research	93.837	University of California, Davis	5UH3HL14180002	493,387	-
Cardiovascular Diseases Research	93.837	University of California, Davis	UH3HL141800	101,567	-
Cardiovascular Diseases Research	93.837	University of California, San Diego	5R25HL14581702	(5,013)	-
Cardiovascular Diseases Research	93.837	University of Chicago	5R01HL12689204	10,991	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	1R01HL14827201A1	46,563	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	5R01HL13490504	21,531	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	5R01HL13490505	28,574	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	5R34HL14692702	10,660	-
Cardiovascular Diseases Research	93.837	University Of Texas Health Science Center At Houston	5R01HL14686002	14,689	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Cardiovascular Diseases Research	93.837	University of Washington, Seattle	1P01HL15132801	375,445	-
Cardiovascular Diseases Research	93.837	Versiti Wisconsin Inc	1P01HL14445701	378,251	-
Cardiovascular Diseases Research	93.837	Versiti Wisconsin Inc	5P01HL14445702	146,909	-
Cardiovascular Diseases Research	93.837	Versiti Wisconsin Inc	5R01HL06883514	53,358	-
Cardiovascular Diseases Research	93.837	Yale University	5U01HL12551103	14,027	-
Lung Diseases Research	93.838			8,843,897	931,897
Lung Diseases Research	93.838	Brigham & Women's Hospital	5U01HL14600202	13,886	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL13474504	35,530	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL13474503	7,778	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	1R01HL14824701A1	603	-
Lung Diseases Research	93.838	Indiana University	5R01HL1482702	26,417	-
Lung Diseases Research	93.838	Indiana University	A345896/PO 2003408357	10,146	-
Lung Diseases Research	93.838	Johns Hopkins University	UM1HL134590	87,350	-
Lung Diseases Research	93.838	Johns Hopkins University	1UG3HL14017701A1	(24,521)	-
Lung Diseases Research	93.838	Massachusetts General Hospital	UG1HL139119	1,667	-
Lung Diseases Research	93.838	Nupeak Therapeutics	1R41HL14952301	18,456	-
Lung Diseases Research	93.838	Renovion Inc.	1R44HL15114401A1	9,290	-
Lung Diseases Research	93.838	University of Arizona	1U01HL3004501	6	-
Lung Diseases Research	93.838	University of Arizona	5U01HL13004503	(1,718)	-
Lung Diseases Research	93.838	University of Arizona	5U01HL13004504	649,269	14,425
Lung Diseases Research	93.838	University of Arizona	5U01HL13004505	122,105	-
Lung Diseases Research	93.838	University of Arizona	5U01HL3004502	(83)	-
Lung Diseases Research	93.838	University of Arizona	5U01HL3004503	(360)	-
Lung Diseases Research	93.838	University of Colorado, Denver	1P01HL15296101	12,830	-
Lung Diseases Research	93.838	University of Michigan	1R01HL15351901	4,940	-
Lung Diseases Research	93.838	University of Michigan	5R01HL14726102	6,107	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill	2U54HL09645816	9,413	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill	5U54HL09645817	121,822	-
Lung Diseases Research	93.838	University Of Texas Health Science Center At Houston	R01HL145025	26,977	-
Blood Diseases and Resources Research	93.839			9,186,988	406,960
Blood Diseases and Resources Research	93.839	Augusta University	2R25HL10636510	7,538	-
Blood Diseases and Resources Research	93.839	Caeli Vascular LLC	1R41HL15096301A1	69,736	-
Blood Diseases and Resources Research	93.839	Emory University	1UG3HL14856001A1	46,450	-
Blood Diseases and Resources Research	93.839	Johns Hopkins University	5R01HL13954303	835	-
Blood Diseases and Resources Research	93.839	Medical College of Wisconsin	5U01HL14347702	15,203	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866002	90,268	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866003	4,154	-
Blood Diseases and Resources Research	93.839	Rutgers University	5U01HL13381704	(11,210)	-
Blood Diseases and Resources Research	93.839	St. Jude Children's Research Institute	5U01HL13399604	59,368	-
Blood Diseases and Resources Research	93.839	University of Alabama	5R01HL13389604	16,072	-
Blood Diseases and Resources Research	93.839	University of Colorado, Denver	4R33HL14179403	39,432	-
Blood Diseases and Resources Research	93.839	University of Pittsburgh	4UH3HL14319202	31,058	-
Blood Diseases and Resources Research	93.839	University of Pittsburgh	5UH3HL14319203	6,658	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5R01HL06883515	12,203	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840			1,285,061	100,578
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	RASD Rwanda	5U24HL13679004	48,338	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Universidad Peruana Cayetano Heredia	1UGHL15237101	99,404	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846			12,616,851	293,130
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Boston University	5R01AR07442802	18,001	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham & Women's Hospital	5U01AR06804305	2,337	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	5R01AR05783608	101,001	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	5R01AR05783609	26,266	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	5R01AR062947408	273,959	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	5R21AR07600802	14,631	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Duke University	1R01AR07299901A1	220,206	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Indiana University	1R01AR07647701	8,558	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Indiana University	5R01AR07647702	7,193	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Integrated Biotherapeutics Inc	1R41A152745	90,800	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR07601302	37,510	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northeast Ohio Medical University	5R01AR0776202	36,287	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Steadman Philippon Research Institute	R21AR072870	(576)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR06906204	48,999	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR06906205	47,458	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR07087304	90,728	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh	5R01AR07614602	74,386	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh	5R21AR07524202	84,706	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Southern California	5R01AR07221203	274,115	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Vanderbilt University	5R01AR06084608	157,989	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Vanderbilt University	7R01AR06084607	24,690	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			40,645,200	3,659,675
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK11525503	79,620	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Baylor Research Institute	1R21DK11136902	4,298	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Bioio LLC	1R42DK12165201A1	237,019	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK09415709	(18)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK09415710	163,238	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars-Sinai Medical Center	3U01DK06241318S1	6,053	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars-Sinai Medical Center	5U01DK06241319	70,277	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Of Philadelphia	5R01DK09783007	28,488	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	2U01DK06614317	9,948	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	5U01DK06614315	(50)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cleveland Clinic Lerner College of Medicine	R01DK122790	200,637	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK061230	17,800	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824608	186,057	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center, Inc	7R01DK06498916	10,963	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Lung Therapeutics	1R43DK12401001A1	70,990	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Mcgill University	5R01DK11073703	5,435	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	5R01DK11549504	5,624	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	5U01DK10483306	23,404	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	5U01DK10086608	7,247	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	5UM1DK10086605REVISED	(2,756)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	NCIRE	1R01DK12564601	35,694	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5P30DK11485703	25,338	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5R01DK09221708	84,911	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5R01DK12574902	25,301	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Platform STL	1R41DK12025301	155,647	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion Therapeutics, Inc	1R44DK12660001	36,394	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion Therapeutics, Inc	R43DK12159801	29,876	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	St. Louis University	5R01DK11040606	181,569	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	State University of New York at Buffalo	5R01DK11448503	38,858	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Alabama, Birmingham	1R01DK12749701	165,753	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Diego	5UH3DK11493304	326,440	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Diego	UH3DK114933	3,007	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Francisco	5R01DK11598702	5,818	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Francisco	5R01DK11598703	32,242	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	1U54DK11861201	133,759	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5P01DK05678818	17,524	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Illinois	1R01DK11008001A1	33,165	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	2U01DK10833406	39,874	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	3U01DK10833405S1	4,617	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	5R01DK11875204	36,396	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	5U01DK10832802	758	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	5U01DK10833407	2,965	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5R01DK106621005	(6)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5R01DK10790405	25,032	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	1R01DK11843101	(1,646)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	1U01DK12665401	14,834	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	2U01DK10322506	3,542	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pittsburgh	5U01DK07214610	(17)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Rochester	1R01DK12068001A1	13,630	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of South Florida	1R01DK12532201A1	1,234	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Southern California	3U01DK10735004	44,849	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Virginia	5R01DK11186104	192,965	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	U2CDK114886	99,582	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Wisconsin, Madison	1R01DK11814501A1	267,179	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University	1R01DK11921201	13,162	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			42,090,469	2,176,320
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS09333405	12,320	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS09333406	18,540	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	California Institute Of Technology	R01NS102279	79,953	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Los Angeles	7R01NS09597906	23,942	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Research Institute	5R01NS11229403	32,776	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cincinnati Children's Hospital Medical Center	5R01NS06280609	1,509	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cincinnati Children's Hospital Medical Center	5R01NS06693202	114	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Collaborations Pharmaceuticals	1R43NS10707901	16,432	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Columbia University	1R01NS11082601A1	42,882	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Columbia University	5R211NS11306303	57,136	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cornell University	5U54NS10071704	3,341	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	5R01NS1158802	(4,504)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	5R01NS1158803	29,360	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54NS11602510	276,062	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54TR00145608	(106,855)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	9U54NS11602509	160,808	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	9U54NS1162509	(5,651)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Freeflow Medical Devices	2R42NS10370402A1	102,724	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hugo W. Moser Research Institute	5K12NS09848204	111,313	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	1U01NS11167801A1	114,354	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5R01NS10629202	3,656	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute	5K12NS09848204	43,437	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute	5K12NS09848205	116,092	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	LA Biomedical	4R33NS09604403	(815)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U01NS11400102	2,339	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS096767	43,100	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS095388	21,029	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Minnetronix Inc.	4R44NS11024702	19,009	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion	1R41NS11364201	83,416	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion	1R41NS11518401	3,406	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mount Sinai School of Medicine	5R01NS09952704	57,833	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5U01NS11385102	7,005	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Oregon Health And Science University	1015486_WUSTL	25,175	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Oregon Health And Science University	5R01NS11194802	179,313	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Phoenix Nest, Inc.	2R44NS08906104	11,982	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Research Foundation For The State University Of New York	1R01NS11801201A1	3,173	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers University	2U24NS09591406	180,024	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers University	5U24MS09591404	(11,250)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Jude Children's Research Institute	1R01NS12111401	27,473	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Louis University	5R01NS11428902	41,813	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Alabama, Birmingham	5U01NS09259504	34,869	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5R01NS094292	(33,537)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5R01NS09429203	(29,130)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U01NS09276403	770	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U01NS09276405	63,881	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	R01NS094292	(43,110)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	1R01NS11626201A1	11,826	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS09904301A1	31,101	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10228901A1	5,066	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10651301A1	2,998	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10665501A1	25,338	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS11072801	4,305	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS11077201	2,174	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS09586902	34,780	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS10069902	2,185	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of North Carolina, Chapel Hill	1R01NS12223001	5,049	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	1U19NS11045601A1	45,671	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	5U19NS11045602	877,882	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh	5R01NS09671404	830	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Southern California	5R01NS03446722	267,855	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Texas Health Science Center At Houston	1R61NS11332901	8,730	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	1U01NS10748601A1	104,579	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Virginia	5R01NS0911804	55,067	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Virginia	5U01NS08803404	79	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Virginia	5U01NS08803405	22,687	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	2R01NS09161806	58,411	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University	1UG3NS11621801	370,915	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Wayne State University	5R01NS09457003	80,579	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS11102902	47,237	-
Allergy and Infectious Diseases Research	93.855			49,077,697	7,510,091
COVID19-Allergy and Infectious Diseases Research	93.855			2,014,781	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute	5UM1AI10956508	6,781	-
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	5U01AI12661402	107,262	-
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	5U01AI12661404	1,052	-
Allergy and Infectious Diseases Research	93.855	Boston University	1R21AI15623601	4,804	-
Allergy and Infectious Diseases Research	93.855	Brigham & Women's Hospital	5UM1AI06863613	(270)	-
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	5R01AI2520205	14,913	-
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	5R21AI13989802	106,245	-
Allergy and Infectious Diseases Research	93.855	Cleveland Clinic Lerner College of Medicine	5R01AI1277404	164,227	-
Allergy and Infectious Diseases Research	93.855	Drexel University	5U19AI12891003	3,493	-
Allergy and Infectious Diseases Research	93.855	Drexel University	5U19AI1289104	33,436	-
Allergy and Infectious Diseases Research	93.855	Duke University	1R01AI13903201	5,804	-
Allergy and Infectious Diseases Research	93.855	Emory University	1U01AI15074701	152,346	-
Allergy and Infectious Diseases Research	93.855	FHI 360	UM1AI068619	699,390	-
Allergy and Infectious Diseases Research	93.855	Fimbrion	5R43AI14983302	17,483	-
COVID19-Allergy and Infectious Diseases Research	93.855	Ichan School of Medicine at Mt. Sinai	HHSN272201400008C	319,221	-
Allergy and Infectious Diseases Research	93.855	Ichan School of Medicine at Mt. Sinai	HHSN272201400008C	25,235	-
Allergy and Infectious Diseases Research	93.855	Ichan School of Medicine at Mt. Sinai	HHSN272201400008C/COA#26	50,830	-
Allergy and Infectious Diseases Research	93.855	Integrated Biotherapeutics Inc	1R41AI5274501A1	81,867	-
COVID19-Allergy and Infectious Diseases Research	93.855	Jackson Laboratory	5U19AI14273302	314,751	-
Allergy and Infectious Diseases Research	93.855	LA Biomedical	1U01AI11640003	129,838	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	1U19AI14279001	294,649	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	5U19AI14279002	58,996	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	5U19AI14279003	51,040	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	RU19AI14279002	425,227	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01AI126610	1,813	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01AI12661004	7,011	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	5U01AI06359416	9,064	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	5U01AI06359417	84,383	-
Allergy and Infectious Diseases Research	93.855	Nanocompositx	1R1AI14787501	8,080	-
Allergy and Infectious Diseases Research	93.855	Newventureiq, Llc	1R41AI14291901	28,787	-
Allergy and Infectious Diseases Research	93.855	Northwestern University	5P30AI11794305	14,689	-
Allergy and Infectious Diseases Research	93.855	Oregon Health And Science University	1R21AI4465801A1	21,285	-
Allergy and Infectious Diseases Research	93.855	Oregon Health And Science University	5R01AI13218602	156,946	-
Allergy and Infectious Diseases Research	93.855	Oregon Health And Science University	5R21AI14465802	15,020	-
Allergy and Infectious Diseases Research	93.855	Salk Institute	2R01AI1040005	201,399	-
Allergy and Infectious Diseases Research	93.855	Salk Institute	5R01AI1040006	169,083	-
Allergy and Infectious Diseases Research	93.855	San Jose State University	1R15AI13814601A1	17,900	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Institute	1U01AI14461601	6,270	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Institute	5U01AI14461602	87,691	-
COVID19-Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Institute	3U01AI14461602S1	271,316	-
Allergy and Infectious Diseases Research	93.855	St. Louis University	1R01AI13019001A1	21,641	-
Allergy and Infectious Diseases Research	93.855	Stanford University	3U01AI13595003S1	19,104	-
Allergy and Infectious Diseases Research	93.855	The George Washington University	1R21AI1377102	2,744	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Allergy and Infectious Diseases Research	93.855	University of Alabama	5U19Al14275903	88,174	-
Allergy and Infectious Diseases Research	93.855	University of Alabama	1U54Al15025501	5,000	-
Allergy and Infectious Diseases Research	93.855	University of Alabama	5U19Al14275902	188,538	-
Allergy and Infectious Diseases Research	93.855	University of Alabama, Birmingham	1U54Al15022501	731	-
Allergy and Infectious Diseases Research	93.855	University of Arizona	5R01Al12994504	22,186	-
Allergy and Infectious Diseases Research	93.855	University of Calgary	R34Al136783	7,521	-
Allergy and Infectious Diseases Research	93.855	University of California, Berkeley	5P01Al10669505	1,444	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	2UM1Al106863615	79,845	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	5U01Al11640002	(2,169)	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	5UM1Al106863614	11,237	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	7UM1Al106863613	7,253	-
COVID19-Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	7UM1Al106863613	347,619	-
Allergy and Infectious Diseases Research	93.855	University Of California, San Diego	7R01Al11463507	1,783	-
Allergy and Infectious Diseases Research	93.855	University of California, San Francisco	2U54Al08297312	75	-
Allergy and Infectious Diseases Research	93.855	University of Chicago	5R01Al12777403	172,478	-
Allergy and Infectious Diseases Research	93.855	University of Colorado	5R01Al106252014	12,600	-
Allergy and Infectious Diseases Research	93.855	University of Colorado, Denver	5R01Al14143602	253,154	-
Allergy and Infectious Diseases Research	93.855	University of Florida	5R01Al14147803	55,267	-
Allergy and Infectious Diseases Research	93.855	University of Kentucky	5R01Al14075804	327,256	-
Allergy and Infectious Diseases Research	93.855	University of Louisville	5R01Al13967103	22,192	-
Allergy and Infectious Diseases Research	93.855	University of Louisville	1R01Al13967101A1	3,069	-
Allergy and Infectious Diseases Research	93.855	University of Mississippi	5R21Al14221003	29,640	-
Allergy and Infectious Diseases Research	93.855	University of North Carolina at Chapel Hill	5U19Al10996505	(369)	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	5R01Al14053903	182,484	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01Al12334807	123,645	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01Al14266203	13,032	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01Al14582802	306,096	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01Al15021402	218,504	-
Allergy and Infectious Diseases Research	93.855	University of Texas Medical Branch at Galveston	5R01Al14635302	177,645	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19Al1427802	481,315	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19Al14278403	306,076	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19Al1478402	92,267	-
Allergy and Infectious Diseases Research	93.855	University of Texas Austin	5R21Al12950502	24,144	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01Al1459601	218,634	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01Al1459603	111,927	-
Allergy and Infectious Diseases Research	93.855	University of Washington, Seattle	5R01Al10400205	(191)	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	1R01Al13251901A1	37,775	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	1R01Al15067801	32,929	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	3UM1Al11427106S1	18,366	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	3UM1Al11427107S1	58,231	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5P01Al13213204	56,707	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5R01Al13864704	32,702	-
COVID19-Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5R01Al15313002	64,202	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1Al11427104	506,063	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1Al11427105	(1,770)	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1Al11427106	7,627	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	3UM1Al14845202S4	34,472	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	1UM1Al14845201	18,517	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5UM1Al14845202	23,140	-
COVID19-Allergy and Infectious Diseases Research	93.855	Vanderbilt University	UM1Al068619	302,932	-
COVID19-Allergy and Infectious Diseases Research	93.855	Vanderbilt University	UM1Al068619 (COVPN)	27,287	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	2UM1Al106943916	266,003	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	501Al12782805	388,834	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1Al106861912	197,025	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1Al106943915	342,965	-
COVID19-Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1Al106943915	202,650	-
Allergy and Infectious Diseases Research	93.855	Washington State University	1U01Al15179901	25,278	-
Allergy and Infectious Diseases Research	93.855	Washington State University	5U01Al15179902	3,654	-
Biomedical Research and Research Training	93.859			27,129,704	359,120
Biomedical Research and Research Training	93.859	Arch Innotek, LLC	1R41GM13027701	1,175	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity	Identification Number		
Biomedical Research and Research Training	93.859	Bio Rankings LLC	2R44GM13148702	239,527	-
Biomedical Research and Research Training	93.859	Bioio LLC	1R41GM13762501	48,748	-
Biomedical Research and Research Training	93.859	Cell Microsystems, Inc	1R41GM13147501	37,386	-
Biomedical Research and Research Training	93.859	Drug Design Methodologies	5R01GM12573602	51,296	-
Biomedical Research and Research Training	93.859	Jackson Laboratory	2R42GM12113302	209,138	-
Biomedical Research and Research Training	93.859	Protein Metrics	1R44GM12543801	(6,397)	-
Biomedical Research and Research Training	93.859	Radiologics	5R01GM13408102	112,476	-
Biomedical Research and Research Training	93.859	University of Alabama, Birmingham	5R25GM13051703	32,240	-
Biomedical Research and Research Training	93.859	University of Colorado, Denver	5R01GM12374604	43,997	-
Biomedical Research and Research Training	93.859	University Of Connecticut	R01NS102633	142,821	-
Biomedical Research and Research Training	93.859	University of Florida	R01GM139046	245,382	-
Biomedical Research and Research Training	93.859	University of Illinois	7R01GM11458805	8,325	-
Biomedical Research and Research Training	93.859	University of Michigan	5R01GM12243404	3,132	-
Biomedical Research and Research Training	93.859	University of Michigan	5R13GM11784503	3,396	-
Biomedical Research and Research Training	93.859	University of Michigan	5U54A15047009	164,348	-
Biomedical Research and Research Training	93.859	University of Michigan	8U54A15047008	9,939	-
Biomedical Research and Research Training	93.859	University of North Carolina, Chapel Hill	1R01GM13728601	33,475	-
Biomedical Research and Research Training	93.859	University of Pittsburgh	2R01GM10861805	103,055	-
Biomedical Research and Research Training	93.859	University of Texas, Austin	5R01GM11423703	46,652	-
Biomedical Research and Research Training	93.859	University of Wisconsin, Madison	5P41GM10853804	6,772	-
Biomedical Research and Research Training	93.859	Vanderbilt University	5R01GM11661606	44,542	-
Child Health and Human Development Extramural Research	93.865			15,829,580	2,892,620
COVID19-Child Health and Human Development Extramural Research	93.865			1,626,016	-
Child Health and Human Development Extramural Research	93.865	Boston Medical Center	5R01HD09506003	34,372	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD07281508	34,528	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09113003	34,995	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09244403	231,721	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Of Philadelphia	1R01HD10152801	23,753	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hospital Medical Center	7R01HD07191506	26,570	-
Child Health and Human Development Extramural Research	93.865	Columbia University	5R01HD09100304	10,461	-
Child Health and Human Development Extramural Research	93.865	Johns Hopkins University	5R01HD09769204	14,245	-
Child Health and Human Development Extramural Research	93.865	Lurie Childrens Hospital	1R21HD09640201A1	(8,331)	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134702	2,759	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134703	33,807	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09597603	5,865	-
Child Health and Human Development Extramural Research	93.865	Nemours Children'S Clinic	5R01HD07846303	5,245	-
Child Health and Human Development Extramural Research	93.865	Newventureiq, Llc	1R41HD09783301	757	-
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	2R01HD07457911	14,612	-
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	2R01HD074579	(699)	-
Child Health and Human Development Extramural Research	93.865	Oregon Health And Science University	1U24HD10098201	47,786	-
Child Health and Human Development Extramural Research	93.865	Oregon Health And Science University	5U24HD10098202	75,797	-
Child Health and Human Development Extramural Research	93.865	Oregon Health And Science University	7R01HD07864107	57,622	-
Child Health and Human Development Extramural Research	93.865	St. Louis College Of Pharmacy	7R01HD07864106	112,771	-
Child Health and Human Development Extramural Research	93.865	Research Foundation For The State University Of New York	5DP1HD08607105	3,455	-
Child Health and Human Development Extramural Research	93.865	University Of Alabama	1R13HD10212801	2,250	-
Child Health and Human Development Extramural Research	93.865	University Of Alabama	5K01HD07958204	1,067	-
Child Health and Human Development Extramural Research	93.865	University Of California, Los Angeles	5R01HD09247104	8,575	-
Child Health and Human Development Extramural Research	93.865	University Of California, Los Angeles	5R01HS09247105	1,274	-
Child Health and Human Development Extramural Research	93.865	University Of California, San Francisco	5R01HD09241904	257,776	-
Child Health and Human Development Extramural Research	93.865	University of Colorado	5R01HD097990-02	31,937	-
Child Health and Human Development Extramural Research	93.865	University Of Indiana	7R01HD08600704	1,460	-
Child Health and Human Development Extramural Research	93.865	University of Maryland, Baltimore	5R03HD09939002	18,188	-
Child Health and Human Development Extramural Research	93.865	University Of Michigan	7R01HD08523303	(38)	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina At Chapel Hill	5R01HD05574113	10,195	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina At Chapel Hill	5R01HD05574115	321,439	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Austin	7U01HD07738406	69,868	-
Child Health and Human Development Extramural Research	93.865	University of Texas Medical Branch at Galveston	5P2CHD06570210	1,603	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Health Science Center At Houston	1R01HD09766901	43,428	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Southwestern Medical Center	5P01HD08438704	258,305	-
Child Health and Human Development Extramural Research	93.865	University Of Virginia	5R01HD07207107	122,937	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity	Total	Passed to Sub-
	Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Child Health and Human Development Extramural Research	93.865	University Of Wisconsin-Madison	1R01HD08300101A1	8,758	-
Child Health and Human Development Extramural Research	93.865	Vanderbilt University	200-2016-91801	15,827	-
Child Health and Human Development Extramural Research	93.865	Vanderbilt University	5U01HD07673306	(12,952)	-
Child Health and Human Development Extramural Research	93.865	Yale University	5R21HD08913102	4,721	-
Child Health and Human Development Extramural Research	93.865	Yale University	5R21HD08913105	103	-
Aging Research	93.866			68,889,901	11,913,304
COVID19-Aging Research	93.866			618,535	-
Aging Research	93.866	Active Life Scientific Inc.	1R22AG07103401	8,871	-
Aging Research	93.866	Baylor College of Medicine	1R01AG06529001A1	119,458	-
Aging Research	93.866	Clear	1R43AG06507501A1	35,316	-
Aging Research	93.866	Cognition Therapeutics, Inc	1RF1AG05778001	356	-
Aging Research	93.866	Columbia University	5U24UA05627005	6,299	-
Aging Research	93.866	Columbia University	5U24UA5627004	86,019	-
Aging Research	93.866	Duke University	2037606	(31)	-
Aging Research	93.866	Duke University	5R24AG05435506	4,503	-
Aging Research	93.866	Harvard School of Public Health	5R01AG06093503	148,862	-
Aging Research	93.866	Hebrew Rehabilitation Center	5R24AG05425905	37,751	-
Aging Research	93.866	Icahn School Of Medicine Mt. Sinai	5U24AG05241104	(2,512)	-
Aging Research	93.866	Icahn School Of Medicine Mt. Sinai	5U24AG05241105	124,363	-
Aging Research	93.866	Indiana University	1U01AG05719501A1	16,548	-
Aging Research	93.866	Indiana University	5U01AG05719504	34,958	-
Aging Research	93.866	Johns Hopkins University	1RF1AG05986901	51,332	-
Aging Research	93.866	Johns Hopkins University	5R01AG04028209	256,610	-
Aging Research	93.866	Mayo Clinic	1U19AG06970101	3,415	-
Aging Research	93.866	Mayo Clinic	5U19AG06391102	2,607	-
Aging Research	93.866	Mayo Clinic	5U19AG06391103	53,894	-
Aging Research	93.866	NCIRE	U19AG024904	297,002	-
Aging Research	93.866	Northwestern University	5R01AG04741604	(534)	-
Aging Research	93.866	Northwestern University	5R01AG04741605S1	7,918	-
Aging Research	93.866	Northwestern University	5R01AG06912002	15,404	-
Aging Research	93.866	Ohio State University	R01AG05619	(3,356)	-
Aging Research	93.866	Oregon Research Institute	5R01AG02004823	19,655	-
Aging Research	93.866	Pennsylvania State University	AG060408	30,119	-
Aging Research	93.866	Regenerative Research Foundation	5R01AG05629305	18,757	-
Aging Research	93.866	Rutgers University	5R01AG0555605	56	-
Aging Research	93.866	St. Louis College of Pharmacy	9RF1AG06076906A1	138,132	-
Aging Research	93.866	St. Louis University	5R01AG05871402	7,219	-
Aging Research	93.866	Stanford University	5R37AG00881631	5,480	-
Aging Research	93.866	Sutter Bay	1R01AG05941601	89,359	-
Aging Research	93.866	University Of California, San Diego	3U19AG010483-26S1	(3,340)	-
Aging Research	93.866	University Of California, San Diego	5U01AG01048326	2,834	-
Aging Research	93.866	University Of California, San Diego	5U19AG010483	3,797	-
Aging Research	93.866	University Of California, San Diego	5U19AG01048326	542	-
Aging Research	93.866	University Of California, San Francisco	1RF1AG059009-01	103,248	-
Aging Research	93.866	University Of California, San Francisco	5P30AG06242202	32,582	-
Aging Research	93.866	University Of California, San Francisco	5R01AG03879110	5,024	-
Aging Research	93.866	University Of California, San Francisco	5R01AG06235903	126,926	-
Aging Research	93.866	University Of Connecticut	5R01AG0688602	9,127	-
Aging Research	93.866	University of Kentucky	5R01AG03865107	20,411	-
Aging Research	93.866	University of Melbourne	1R01AG05867602	254,512	-
Aging Research	93.866	University of Miami	5R01AG06461403	223,312	-
Aging Research	93.866	University of Michigan	1R01AG06258201A1	446	-
Aging Research	93.866	University of Missouri	R01AG059818	8,266	-
Aging Research	93.866	University Of Nevada Reno	3P01AG05144303S1	(23,816)	(15,316)
Aging Research	93.866	University Of Pennsylvania	1R01AG06857701	11,291	-
Aging Research	93.866	University Of Pennsylvania	5R01AG05443503	326,465	-
Aging Research	93.866	University Of Pittsburgh	1R01AG06487701A1	51,823	-
Aging Research	93.866	University Of Pittsburgh	1R56AG06487701	611,993	-
Aging Research	93.866	University Of Pittsburgh	1U19AG06805401	164,550	-
Aging Research	93.866	University Of Pittsburgh	3U01AG051406-05S3	11,232	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Aging Research	93.866	University Of Pittsburgh	5R01AG06049904	449,408	-
Aging Research	93.866	University Of Pittsburgh	5U01AG05140605	412,121	-
Aging Research	93.866	University Of Pittsburgh	5U01AG05140605S4	24,824	-
Aging Research	93.866	University Of Southern California	1R01AG05379801A1	4,082	-
Aging Research	93.866	University Of Southern California	1R01AG06184801	2,655	-
Aging Research	93.866	University Of Southern California	1R01AG06368901	17,752	-
Aging Research	93.866	University Of Southern California	1R56AG05872601A1	49,410	-
Aging Research	93.866	University Of Southern California	1R61AG06654301	37,415	-
Aging Research	93.866	University Of Southern California	2U19AG02490413	13,718	-
Aging Research	93.866	University Of Southern California	5P01AG05235002	98,302	-
Aging Research	93.866	University Of Southern California	5P01AG05235003	32,679	-
Aging Research	93.866	University Of Southern California	5R01AG05379803	945	-
Aging Research	93.866	University Of Southern California	5R01AG05379804	13,677	-
Aging Research	93.866	University Of Southern California	5R01AG05402902	630	-
Aging Research	93.866	University Of Southern California	5U24AG05743704	128,806	-
Aging Research	93.866	University Of Texas Southwestern Medical Center	5R01AG04974905	300,115	-
Aging Research	93.866	University Of Texas Southwestern Medical Center	5R01AG04867806	360,460	-
Aging Research	93.866	University of Toledo	R13AG069353	26,312	-
Aging Research	93.866	University of Utah	1U01CA20611005	230,542	-
Aging Research	93.866	University Of Virginia	5R01AG06804802	191,026	-
Aging Research	93.866	University Of Washington	3U01AG01697620S9	1,029	-
Aging Research	93.866	University Of Washington	3U01AG01697620SA	25,300	-
Aging Research	93.866	University Of Washington	5R01AG06375902	15,348	-
Aging Research	93.866	University of Wisconsin, Madison	1R01AG07002801	21,714	-
Aging Research	93.866	University of Wisconsin, Madison	1R01AG07088301	6,036	-
Aging Research	93.866	Yale University	1R61AG06982201	98,362	-
Aging Research	93.866	Yale University	5R01AG06591702	139,952	-
Aging Research	93.866	Yale University	5R61AG06982202	19,132	-
Vision Research	93.867			9,159,261	424,064
Vision Research	93.867	Duke University	5R01FY02500904	7,657	-
Vision Research	93.867	Eyenuk LLC	1R43EY02484801	9	-
Vision Research	93.867	Jaeb Center for Health Research Foundation	U10EY11751	68	-
Vision Research	93.867	New York University School of Medicine	1U10EY02686901	564	-
Vision Research	93.867	University Of California, Irvine	2R01EY00933932	28,881	-
Vision Research	93.867	University Of California, Irvine	5R24EY02728304	104,215	-
Vision Research	93.867	University Of California, San Diego	5R21EY03112502	25,289	-
Vision Research	93.867	University Of Massachusetts	5R01EY02860203	93,576	-
Vision Research	93.867	University Of Michigan	5R01Y02664105	6,236	-
Vision Research	93.867	University of Missouri	1R21EY02910601A1	125,847	-
Vision Research	93.867	West Virginia University	1UG1EY03165401	12,506	-
Medical Library Assistance	93.879			542,616	94,902
Medical Library Assistance	93.879	California Institute of Technology	5U01LM01267203	16,568	-
Medical Library Assistance	93.879	University of Arkansas	5R01LM01248204	62,124	-
Global Health Research and Research Training	93.989			298,061	41,040
Global Health Research and Research Training	93.989	Asociaion Benefica Prisma	1D71TW01120501	(100)	-
Global Health Research and Research Training	93.989	Regional Allience for Sustainable Development (RASD) Rwanda	5D43TW01033504	52,833	-
Fogarty International Center	93.RD			34,019	23,250
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91020F00030	584	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91019D00024-7591029F00	132	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	HHSN261201500003I	531,844	-
National Cancer Institute (NCI)	93.RD	Massachusetts General Hospital	218211	(68)	-
National Cancer Institute (NCI)	93.RD	Massachusetts General Hospital	220778	137,384	-
National Cancer Institute (NCI)	93.RD	Massachusetts General Hospital	2U19CA02123939	(29,447)	-
National Cancer Institute (NCI)	93.RD	Westat	6426S10	12,306	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	L3 Healthcare	75N92021P00049	1,957	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	L3 Healthcare	75N92021D0008	30,152	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	University of Michigan	50000019445	115,503	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			2,250,371	912,516
COVID19-National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			107,257	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Emory University	5R01AI12520201	24,998	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93019C00051	149,297	-
COVID19-National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93019C00051	697,025	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Infectious Disease Research Institute	HHSN272201400041C	220,292	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	HHSN272201700060C	661,077	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Rutgers University	HHSN271201800023I	387,951	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	St. Jude Children's Research Institute	HHSN272201400006C	589,733	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201100038C	100	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201600017C	9,932	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201600018C	2,627	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Montana	HHSN272201400050C	265,951	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Vanderbilt University Medical Center	75N93019C000074	218,210	-
National Institute of Child Health and Human Development (NICHD)	93.RD	Duke University	HHSN275201800003I	55,523	-
National Institute of Child Health and Human Development (NICHD)	93.RD	Duke University	HHSN2752000003	(5,134)	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93.RD	Remd Biotherapeutics, Inc.	2R44DK108305	(149,849)	-
National Institutes of Health (NIH)	93.RD			5,212	-
National Institutes of Health (NIH)	93.RD	Adjuvance Technologies	HHSN272201700066C	47,057	-
National Institutes of Health (NIH)	93.RD	Brigham & Women's Hospital	5UM1A106863612	191	-
National Institutes of Health (NIH)	93.RD	CARG	5R33AG05020604	8,964	-
National Institutes of Health (NIH)	93.RD	Children's Hospital Of Philadelphia	FP23769SUB1301 (FURTH)	1,670	-
National Institutes of Health (NIH)	93.RD	Cleveland Clinic Lerner College of Medicine	1375-SUB	72,630	-
National Institutes of Health (NIH)	93.RD	Duke University	HHSN275201000003I	35,231	-
National Institutes of Health (NIH)	93.RD	Ecog-Acrin Medical Research Foundation	PDS137629	15,233	-
National Institutes of Health (NIH)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93021C00014	7,120	-
National Institutes of Health (NIH)	93.RD	Mathmatica	HHS233201500035I/HHSP233	2,631	-
National Institutes of Health (NIH)	93.RD	New York University	0T2HL156812	6,882	-
National Institutes of Health (NIH)	93.RD	Oregon Health And Science University	Unknown	6,459	-
National Institutes of Health (NIH)	93.RD	Radiologics	75N91020C00025	52,200	-
National Institutes of Health (NIH)	93.RD	RTI International	10THL15681201	8,408	-
National Institutes of Health (NIH)	93.RD	RTI International	888-15-16-16	(23,355)	-
National Institutes of Health (NIH)	93.RD	University Of California, San Diego	5R01MH11821702	262,096	-
National Institutes of Health (NIH)	93.RD	University Of California, San Diego	7R21AL15204902	48,967	-
National Institutes of Health (NIH)	93.RD	University Of California, San Diego	Ko8HD099314	13,072	-
COVID19-National Institutes of Health (NIH)	93.RD	University of Cincinnati	10THL15681201	1,191	-
National Institutes of Health (NIH)	93.RD	University of Texas MD Anderson	3001480923	(4,136)	-
National Institutes of Health (NIH)	93.RD	Vivent	RWB_VIVENTTOWU_FY20-21	66,312	-
National Institutes of Health (NIH)	93.RD	Westat	HHSN261201600007I	12,343	-
National Institutes of Health (NIH)	93.RD	Yale University		21,139	-
National Institutes of Health (NIH)	93.RD	Yale University	AG058926	2,499	-
Substance Abuse and Mental Health Services Administration					
Projects of Regional and National Significance	93.243			124,094	-
Substance Abuse and Mental Health Services Administration	93.RD	St. Louis County	SAMHSA	9,339	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				551,665,549	54,600,215
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION					
National Aeronautics and Space Administration					
Science	43.001			6,966,572	788,396
Science	43.001	Bay Area Environmental Research	NASA80NSSC18K1082	29,329	-
Science	43.001	California Institute of Technology	80NSSC18K0223	94,280	-
Science	43.001	California Institute of Technology	80NSSC20K0540	23,159	-
Science	43.001	Jet Propulsion Laboratory	1617863	8,240	-
Science	43.001	Jet Propulsion Laboratory	1628233	56,112	-
Science	43.001	Jet Propulsion Laboratory	1639746	17,425	-
Science	43.001	Jet Propulsion Laboratory	1639750	36,913	-
Science	43.001	Jet Propulsion Laboratory	1649883	91,011	-
Science	43.001	Planetary Science Institute	80NSSC17K0343	14,354	-
Science	43.001	Rensselaer Polytechnic Institute	80NSSC19M0069	7,339	-
Science	43.001	Smithsonian Astrophysical Observatory	G0920047B	10,248	-
Science	43.001	Smithsonian Astrophysical Observatory	G0920095A	1,504	-
Science	43.001	Smithsonian Astrophysical Observatory	G0021046A	9,303	-
Science	43.001	Smithsonian Astrophysical Observatory	G0021103A	18,880	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Science	43.001	Smithsonian Astrophysical Observatory	GO516051A	3,780	-
Science	43.001	Smithsonian Astrophysical Observatory	GO920034X	8,813	-
Science	43.001	Smithsonian Astrophysical Observatory	NAS8-03060	9,762	-
Science	43.001	Smithsonian Astrophysical Observatory	TM1-22003X	9,759	-
Science	43.001	University of Chicago	80NSSC21M0116	3,135	-
Science	43.001	University of New Mexico	80NSSC19K0958	68,956	-
Space Operations	43.007			305,930	-
Education	43.008	Missouri University of Science and Technology	NNX14AN17A	(689)	-
Education	43.008	Missouri University of Science and Technology	NNX15AK03H	65,625	-
Education	43.008	Missouri University of Science and Technology	80NSSC20M0100	35,067	-
Space Technology	43.012			246,379	-
NASA	43.RD	Applied Particle Technology	80NSSC20C0546	544	-
NASA	43.RD	Arizona State University	NNG07EK00C	126,234	-
NASA	43.RD	Jet Propulsion Laboratory	1658021	8,223	-
NASA	43.RD	Jet Propulsion Laboratory	JPL1638305	14,544	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710630	37,168	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710805	72,659	-
NASA	43.RD	Jet Propulsion Laboratory	NNN12AA01C	223,038	-
NASA	43.RD	Johns Hopkins University	1277793	87,191	-
NASA	43.RD	Southwest Research Institute	NASW02008	68,512	-
NASA	43.RD	Southwest Research Institute	NNN12AA01C	24,839	-
NASA	43.RD	University of Texas Austion	NNM16AA26C	9,529	-
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINSTRATION				8,813,667	788,396
NATIONAL SCIENCE FOUNDATION					
National Science Foundation					
National Science Foundation	47.RD			35,534	-
Engineering Grants	47.041			3,555,471	392,028
Engineering Grants	47.041	ONU Technology Inc.	2028008	14,802	-
Engineering Grants	47.041	Thermoai Inc	1938485	22,272	-
Engineering Grants	47.041	University of Central Florida	1908167	34,847	-
Engineering Grants	47.041	University of Illinois	1900277	34,242	-
Engineering Grants	47.041	University of Pennsylvania	CMMI1548571	810,018	-
Mathematic and Physical Sciences	47.049			2,737,939	32,057
Mathematic and Physical Sciences	47.049	Barnard College	1828168	(4,533)	-
Mathematic and Physical Sciences	47.049	University of Minnesota	CHE1906135	214,555	-
Geosciences	47.050			1,217,848	20,128
Geosciences	47.050	Columbia University	OPP1743310	7,098	-
Geosciences	47.050	Cornell University	1654568	19,921	-
Computer and Information Science and Engineering	47.070			2,741,611	21,105
Computer and Information Science and Engineering	47.070	George Mason University	1927422	26,661	-
COVID19-Computer and Information Science and Engineering	47.070	Georgia Institute of Technology	IIS2027689	14,788	-
Computer and Information Science and Engineering	47.070	University of California, Berkely	NSF1640899	214,980	168,265
Computer and Information Science and Engineering	47.070	University of Texas at Austin	1550593	24,345	-
Computer and Information Science and Engineering	47.070	University of Utah	1564287	43,167	-
Computer and Information Science and Engineering	47.070	University of Utah	1622741	18,988	-
Computer and Information Science and Engineering	47.070	University of Utah	162688	15,600	-
Computer and Information Science and Engineering	47.070	University of Utah	2002158	77,580	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS182688	60,660	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS1827940	6,445	-
Computer and Information Science and Engineering	47.070	Virginia Polytech Institute	ACL4547580	53,048	-
Biological Sciences	47.074			4,521,999	609,610
Biological Sciences	47.074	American University	1948181	9,399	-
Biological Sciences	47.074	Baylor College of Medicine	DBI2021795	89,425	-
Biological Sciences	47.074	University of Wisconsin, Madison	1818040	35,203	-
Biological Sciences	47.074	University of Wisconsin, Madison	1840687	188,452	-
Social, Behavioral, and Economic Sciences	47.075			771,612	25,551
Social, Behavioral, and Economic Sciences	47.075	Georgia State University	1740201	35,568	-
Social, Behavioral, and Economic Sciences	47.075	University of Texas at Austin	1638822	7,072	-
Education and Human Resources	47.076			2,088,388	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Education and Human Resources	47.076	Harris-Stowe State University	1619639	181,376	-
Education and Human Resources	47.076	Jackson State University	2000135	12,627	-
Education and Human Resources	47.076	University of Alabama	1915544	42,828	-
Education and Human Resources	47.076	University of Wisconsin	1726625	5,531	-
Polar Programs	47.078			8,587	-
Office of International Science and Engineering	47.079			49,187	-
Office of International Science and Engineering	47.079	CFDF Global	OISE9531011	249	-
COVID19-Office of International Science and Engineering	47.079	University of Wisconsin	OISE20665901	49,033	-
Office of Integrative Activities	47.083	University of Missouri	OIA-1355406	(332)	-
TOTAL NATIONAL SCIENCE FOUNDATION				20,094,091	1,268,744
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Agency for International Development					
Agency for International Development Foreign Assistance for Programs Overseas	98.001	CARE	720FDA19GR00221	30,030	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Michigan State University	7200AA18LE0003	63,973	48,224
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Mississippi State University	7200AA18CA00030	151,053	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	National Academy of Sciences	AID263A1500002	29,467	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Purdue University	AID7200AA18CA00009	44,141	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Task Force for Global Health	AIDOAG1400008	11,169	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	University of Georgia	7200AA18CA00003	111,325	-
Agency for International Development	98.RD	Transcultural Psychosocial Organization	AID-OAA-A-17-00002	57,176	-
DEPARTMENT OF AGRICULTURE					
National Institute of Food and Agriculture					
Biotechnology Risk Assessment Research	10.219			133,440	-
Agriculture and Food Research Initiative (AFRI)	10.310			245,132	-
Agriculture and Food Research Initiative (AFRI)	10.310	Iowa State University	20156800123242	28,438	-
Agriculture and Food Research Initiative (AFRI)	10.310	University of Hawaii	2020-67022-31146	74,215	-
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT					
Department of Housing and Urban Development					
Office of Healthy Homes and Lead Hazard Control	14.906			78,695	15,345
DEPARTMENT OF THE INTERIOR					
U.S. Geological Survey					
Assistance to State Water Resources Research Institutes	15.805	University of Missouri	G16AP00066	17,701	-
DEPARTMENT OF JUSTICE					
Community Based Violence Prevention Programs	16.123	City of St. Louis	18-51	11,221	-
DEPARTMENT OF STATE					
Overseas Refugee Assistance Programs for Strategic Global Priorities	19.522			67,787	-
DEPARTMENT OF TRANSPORTATION					
Federal Highway Administration					
National Highway Traffic Safety Administration	20.RD	Wake Forest University	DTNH2217D00070	29,841	-
DEPARTMENT OF VETERANS AFFAIRS					
Department of Veterans Affairs	64.RD			132,884	-
ENVIRONMENTAL PROTECTION AGENCY					
Office of Research and Development					
Environmental Protection Agency	66.RD			(3,065)	-
Science to Achieve Results (STAR) Research Program	66.509			229,042	-
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Arts Grants to Organizations and Individuals	45.024			1,260	-
Promotion of the Humanities - Fellowships and Stipends	45.160			30,001	-
Promotion of the Humanities - Office of Digital Humanities	45.169	University of Maine	HAA26129018	14,156	-
Department of Homeland Security					
Department of Homeland Security	97.RD	Surescan	HSHQDC14CB011	10	-
Total Research & Development Cluster				610,903,627	60,293,541
Other Sponsored Programs					
DEPARTMENT OF DEFENSE					
Department of Defense					
Department of Defense	12.U01	Entegriion	W81XWH16C0162	25,115	-
U.S. Army Medical Command					
Military Medical Research and Development	12.420	Boston Children's Hospital	W81XWH1710532	25,263	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
Military Medical Research and Development	12.420	University of Alabama Birmingham	W81XWH1720037	320	-
Military Medical Research and Development	12.420	University of Colorado	W81XWH1510504	110,502	-
TOTAL MILITARY MEDICAL RESEARCH AND DEVELOPMENT				136,085	-
TOTAL DEPARTMENT OF DEFENSE				161,200	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Children and Families					
Affordable Care Act Personal Responsibility Education Program	93.092			3,148	-
Administration for Community Living					
Alzheimer's Initiative	93.763	Memory Home Care Solutions	90ADPI00210100	1,393	-
Centers for Disease Control					
Autism and Other Developmental Disabilities	93.998			391,720	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD00115505	12,542	-
Capacity Building Assistance for High-Impact HIV Prevention	93.834			266	-
COVID19-Centers for Disease Control and Prevention	93.U01			16,038	-
Centers for Disease Control and Prevention	93.U02			389,080	-
Centers for Disease Control and Prevention	93.U03			151,310	-
Centers for Disease Control and Prevention	93.U04	Boston Children's Hospital	75D30120C07725	777	-
Centers for Disease Control and Prevention	93.U05	Home State Health	2A2CMS3317710101	17,169	-
Centers for Disease Control and Prevention	93.U06	Missouri Department of Health and Human Services	DH1907A0002	351,151	72,079
Centers for Disease Control and Prevention	93.U07	Summit (Oxford) Limited	1009191	26,272	-
Centers for Disease Control and Prevention	93.U08	Vivent	DH200048379 RFA 2023	149,677	-
COVID19-Emerging Infections Sentinel Networks	93.860	Olive View	1U01CK00048001	74,487	-
Colorectal Cancer Screening Program	93.800	University of Missouri	1 NU58DP0067650100	12,609	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	20-22	39,149	-
Food and Drug Administration					
Food and Drug Administration	93.U09			28,556	-
Food and Drug Administration	93.U10			148,575	-
Health Resources and Services Administration					
Health Resources and Services Administration	93.U11	ACRW	DH1713A0001	77	-
Health Resources and Services Administration	93.U12	City of St. Louis	19-30	(48)	-
Health Resources and Services Administration	93.U13	Health Research Inc.	15-0898-03	18,405	-
Health Resources and Services Administration	93.U14	St. Clair County	UNKNOWN	15,671	-
Trans-NIH Research Support	93.110	University of Texas Health Science Center At San Antonio	5H30MC240510700	18,214	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC226840901	(12,191)	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC226841001	111,313	-
TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN				99,122	-
COVID19-Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			93,459	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			1,235,228	108,132
TOTAL COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH				1,328,687	108,132
COVID19-Sickle Cell Treatment Demonstration Program	93.365			23,038	-
Sickle Cell Treatment Demonstration Program	93.365			534,901	344,435
				557,939	344,435

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	21-84	358,676	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2H89HA000332400	51,392	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2H89HA000332700	776,996	-
TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS				1,187,064	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	X07HA00030	93,329	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	DH200048389	144,808	-
HIV Care Formula Grants	93.917	St. Clair County	X07HA00132700	90,665	-
HIV Care Formula Grants	93.917	St. Clair County	RYAN WHITE HIV/AIDS	(105)	-
TOTAL HIV CARE FORMULA GRANTS				328,697	-
COVID19-Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			138,813	-
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			626,643	22,994
				765,456	22,994
Special Projects of National Significance	93.928			435,147	6,000
National Heart, Lung and Blood Institute	93.U15			43,199	-
Office of Minority Health					
Community Programs to Improve Minority Health	93.137	St. Louis Integrated Health	1CPIMP1611360300	55,321	-
Office of Population Affairs					
Family Planning Services	93.217	Missouri Family Health Council	FHPHA006455	51,648	-
Family Planning Services	93.217	Missouri Family Health Council	FHPHA006455	192,925	-
TOTAL FAMILY PLANNING SERVICES				244,573	-
Office of the Secretary of Health and Human Services					
COVID19-Biomedical Advanced Research and Development Authority (BARDA)	93.U16	Duke University	HHS0100201400002I	593,534	-
Substance Abuse and Mental Health Services Administration					
Substance Abuse and Mental Health Services_ Projects of Regional and National Significance	93.243			348,866	-
State Targeted Response to the Opioid Crisis Grants	93.788	University of Missouri, St. Louis	1H79TI0816702	46,663	-
State Targeted Response to the Opioid Crisis Grants	93.788	University of Missouri, St. Louis	AOC21380034	115,876	-
				162,539	-
Substance Abuse and Mental Health Services Administration	93.U17	St. Louis County Department of Health	HE20200169	6,136	-
Substance Abuse and Mental Health Services Administration	93.U18	Vision for Children at Risk	VCRSTLPL	195,042	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				8,217,560	553,640
OTHER FEDERAL PROGRAMS					
DEPARTMENT OF HOMELAND SECURITY					
Countering Weapons of Mass Destruction	97.077	City of St. Louis	19DHRV000010100	230,630	-
DEPARTMENT OF JUSTICE					
Office of Juvenile Justice and Delinquency Prevention					
Community-Based Violence Prevention Program	16.123	United Way of Greater St. Louis	2016MUMUK012	(345)	-
Community-Based Violence Prevention Program	16.123	United Way of Greater St. Louis	2017MUMUK006	41,915	-
				41,570	-
Second Chance Act Reentry Initiative	16.812	Soulfisher Minsity	2018CYBX0018	25,704	-
DEPARTMENT OF LABOR					
Department of Labor	17.U01	The Ahima Foundation	AP278251560A17	48,459	-
DEPARTMENT OF THE TREASURY					
Internal Revenue Service					
Low Income Taxpayer Clinics	21.008			97,278	-
NATIONAL ARCHIVES AND RECORDS ADMINISTRATION					
National Archives and Records Administration					
National Archives and Records Administration	89.U01	National Film Preservation Foundation	FED18022	13	-
NATIONAL ENDOWMENT FOR THE ARTS					
Promotion of the Arts Grants to Organizations and Individuals	45.024			56,544	-
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Humanities Federal/State Partnership	45.129			15,000	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Promotion of the Humanities Division of Preservation and Access	45.149			114,297	42,001
Total Other Sponsored Programs from Other Federal Agencies				629,495	42,001
Total Other Sponsored Programs				9,008,255	595,641
Student Financial Assistance Cluster					
DEPARTMENT OF EDUCATION					
Federal Supplemental Educational Opportunity Grant	84.007			1,088,576	-
Federal Work-Study Program	84.033			1,283,658	-
Federal Pell Grant Program	84.063			5,298,541	-
Teacher Education Assistance for College and Higher Education Grants	84.379			50,866	-
Federal Direct Student Loans					
Outstanding Loans as of July 1, 2020	84.268			-	-
New Loans Issued during 2021	84.268			70,257,627	-
Administrative Cost Allowance	84.268			-	-
Federal Perkins Loans					
Outstanding Loans as of July 1, 2020	84.038			14,974,777	-
New Loans Issued during 2021	84.038			-	-
Administrative Cost Allowance	84.038			-	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Health Professions Student Loans including Primary Care Loans/Loans for Disadvantaged Students					
Outstanding Loans as of July 1, 2020				41,611	-
New Loans Issued during 2021	93.342			-	-
Administrative Cost Allowance	93.342			-	-
Total Student Financial Assistance Cluster				92,995,656	-
DEPARTMENT OF EDUCATION					
COVID 19 Higher Education Emergency Relief Fund - Student Aid Portion	84.425E			4,539,870	-
COVID 19 Higher Education Emergency Relief Fund - Institutional Portion	84.425F			-	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
COVID 19 Claims Reimbursement for the Uninsured Program	93.461			407,916	-
COVID 19 Provider Relief Fund	93.498			51,747,479	-
Highway Safety Cluster					
DEPARTMENT OF TRANSPORTATION					
Police Traffic Services	20.600	Missouri Dept of Transportation	20DL02001	33,677	-
Total Highway Safety Cluster				33,677	-
TRIO Cluster					
DEPARTMENT OF EDUCATION					
TRIO - Student Support Services	84.042			294,257	-
Medicaid Cluster					
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Medical Assistance Program	93.778	Missouri Department of Health and Senior Services	ER100160099	-	-
Total Federal Award Expenditures				769,930,737	60,889,182

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2021

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the expenditures of Washington University (the "university") under programs of the Federal Government for the year ended June 30, 2021. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements. The university includes the amounts in the Schedule in the net assets without donor restrictions of the university's Consolidated Statement of Activities for the year ended June 30, 2021.

The Schedule is prepared on the accrual basis of accounting. Assistance Listing and pass-through numbers are provided when available. Negative amounts presented as expenditures represent subsequent period adjustments, transfers, or vendor credits. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts and similar agreements.

2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 25.5% to 57.5%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2021.

3. Federal Student Loan Programs

The following schedule includes the SFA loan balances outstanding as of June 30, 2021:

Student Financial Aid	Federal Assistant Listing Number	Outstanding Balances
U.S. Department of Education		
Federal Perkins Loan Program	84.038	14,974,777
U.S. Department of Health and Human Services		
Health Profession Student Loans, Primary Care Loans	93.342	41,611

4. Provider Relief Fund

The Schedule includes grant activity related to the Department of Health and Human Services ("HHS") Coronavirus Aid Relief and Economic Security (CARES) Act Assistance Listing Number 93.498. As required based on guidance in the 2021 OMB Compliance Supplement, the Schedule includes all Period 1 funds received between April 10, 2020 and June 30, 2020 and expended by June 30, 2021 as reported to HRSA via the PRF Reporting Portal. The Schedule thus includes \$51,747,000 in lost revenue.

Report on Compliance and on Internal Controls



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statement of position as of June 30, 2021, and the related consolidated statements of activities and of cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 4, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered University's internal control over financial reporting ("internal control") as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of University's internal control. Accordingly, we do not express an opinion on the effectiveness of University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the University's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether University's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

St. Louis, Missouri
October 4, 2021



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal
Control Over Compliance in Accordance with the Uniform Guidance**

To the Board of Trustees of Washington University

Report on Compliance for Each Major Federal Program

We have audited Washington University's (the "University") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2021. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the University's compliance.

Opinion on Each Major Federal Program

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.

Other Matters

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 10 "Gramm-Leach-Bliley Act-Student Information Security." This section includes three suggested audit procedures with respect to



verification that the institution (1) designated an individual to coordinate the information security program, (2) performed a risk assessment that addresses the three required areas in 16 CFR 314.4(b), and (3) documented a safeguard for each risk identified. Our procedures in relation to these three items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these three items. Our procedures did not include an analysis of the adequacy or completeness of the risk assessment performed or the safeguards for each risk identified by management.

Report on Internal Control Over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

St. Louis, Missouri
April 22, 2022

Schedule of Findings and Questioned Costs

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2021

Part I - Summary of Auditors' Results

Financial Statements

Type of auditors' report issued: Unmodified

Internal control over financial reporting:

Material weakness (es) identified? Yes No

Significant deficiency (ies) identified not considered to be material weaknesses? Yes None reported

Noncompliance material to financial statements noted? Yes No

Federal Awards

Type of auditors' report issued on compliance for major programs: Unmodified

Internal control over major programs:

Material weakness (es) identified? Yes No

Significant deficiency (ies) identified not considered to be material weaknesses? Yes None reported

Any audit findings disclosed that are required to be reported in accordance with Uniform Guidance Section 200.516(a)? Yes No

Identification of Major Programs:

Assistance Listing Number(s)	Name of Federal Program or Cluster
Various	Research and Development Cluster/
Various	Student Financial Assistance/
84.425E	COVID 19 Higher Education Emergency Relief Fund-Student Aid Portion,
93.498	COVID 19 Provider Relief Fund/
93.914	Ryan White
Dollar threshold used to distinguish between Type A and Type B programs:	\$3,000,000
Auditee qualified as low-risk auditee?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2021

Part II – Financial Statement Findings

There are no financial statement findings to report.

Part III – Federal Award Findings and Questioned Costs

There are no federal award findings and questioned costs to report.

Summary Schedule of Prior Audit Findings and Status

Washington University
Summary Schedule of Prior Audit Findings and Status
For the Year Ended June 30, 2021

Part III – Federal Award Findings

There were no federal award findings and questioned costs in prior years that require an update in this report.